付録 2.7.4-60 有害事象の要約（AEOSI- 肺臓炎）
041 試験（APaT 集団）

	Subjects With Advanced Melanoma	
	n	(%)
Subjects in population	42	
with one or more adverse events	1	(2.4)
with no adverse event	41	(97.6)
with drug-related† adverse events	1	(2.4)
with toxicity grade 3-5 adverse events	0	(0.0)
with toxicity grade 3-5 drug-related adverse events	0	(0.0)
with serious adverse events	1	(2.4)
with serious drug-related adverse events	1	(2.4)
who died	0	(0.0)
who died due to a drug-related adverse event	0	(0.0)
discontinued‡ due to an adverse event	1	(2.4)
discontinued due to a drug-related adverse event	1	(2.4)
discontinued due to a serious adverse event	1	(2.4)
discontinued due to a serious drug-related adverse event	1	(2.4)

†Determined by the investigator to be related to the drug.

‡Study medication withdrawn.

MedDRA preferred terms "Neoplasm Progression", "Malignant Neoplasm Progression" and "Disease Progression" not related to the drug are excluded.

(Database Cutoff Date: [redacted].

Data Source: [資料5.3.5.2.3: P041V01]

付録 2.7.4-61 Grade 別有害事象（AEOSI-肺臓炎）（発現割合 0%超）
041 試験（APaT 集団）

	Subjects With Advanced Melanoma	
	n	(%)
Subjects in population	42	
with one or more adverse events	1	(2.4)
with no adverse events	41	(97.6)
Respiratory, thoracic and mediastinal disorders	**1**	**(2.4)**
Grade 2	1	(2.4)
Pneumonitis	1	(2.4)
Grade 2	1	(2.4)

Every subject is counted a single time for each applicable specific adverse event. A subject with multiple adverse events within a system organ class is counted a single time for that system organ class.

A system organ class or specific adverse event appears on this report only if its incidence in one or more of the columns is greater than or equal to the incidence specified in the report title, after rounding.

Only the highest reported grade of a given adverse event is counted for the individual subject.

Grades are based on NCI CTCAE version 4.0.

MedDRA preferred terms "Neoplasm Progression", "Malignant Neoplasm Progression" and "Disease Progression" not related to the drug are excluded.

Adverse event terms are from MedDRA Version 18.0.

(Database Cutoff Date: [redacted].

Data Source: [資料5.3.5.2.3: P041V01]

C Confidential

付録 2.7.4-62 AEOSI-肺臓炎が発現するまでの期間及び罹患時間の要約
041 試験（APaT 集団）

	Subjects With Advanced Melanoma n	(%)
Subjects in population	42	
Subjects with Pneumonitis	1	(2.4)
Time to Onset of First Pneumonitis† (days)		
Mean (Std)	84.0	
Median (Range)	84.0 (84, 84)	
Total episodes of Pneumonitis	1	
Average Episodes per Subject	1.00	
Episode duration‡ (days)		
Median (Range)	288.0 (288, 288)	

(%) = Number of patients with Pneumonitis / Number of patients in population.

† Time to onset statistics are based on number of patients with Pneumonitis.

‡ Episode duration is based on a time-to-event analysis. If an adverse event is not resolved at the time of analysis or the patient died without adverse event resolved, the duration is censored at either data cutoff date or date of death, whichever occurred first.

Std = Standard Deviation.

Grades are based on NCI CTCAE version 4.0.

(Database Cutoff Date: [redacted].

Data Source: [資料5.3.5.2.3: P041V01]

C Confidential

付録 2.7.4-63 AEOSI の一覧

041 試験（APaT 集団）

Subject ID	Onset Epoch	Rel Day of Onset	Adverse Event	Duration	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome	Treated with sysytemic corticosteroid	Starting dose of sysytemic corticosteroid
MK-3475 2 mg/kg Q3W											
Colitis											
Trial Number=3475-041, Site Number=0001, Subject ID=041001, Gender=Male, Race=Asian, Age=67 Years, Rel Day of Last Recorded Dose of Study Medication=385, PD-L1=Unknown, Melanoma Type=Advanced Cutaneous, BRAF=Wild Type, NRAS=, c-KIT=											
041001	Treatment Cycle 7	137	Colitis	1.97 Months	3	Y	Y	Interrupted	Resolved	Y	High Dose
Trial Number=3475-041, Site Number=0007, Subject ID=041025, Gender=Male, Race=Asian, Age=49 Years, Rel Day of Last Recorded Dose of Study Medication=275, PD-L1=PD-L1 Positive, Melanoma Type=Advanced Cutaneous, BRAF=Wild Type, NRAS=Wild Type, c-KIT=											
041025	Treatment Cycle 14	276	Colitis	Continuing	2	N	Y	Interrupted	Not Resolved	Y	Low Dose
Hyperthyroidism											
Trial Number=3475-041, Site Number=0005, Subject ID=041013, Gender=Male, Race=Asian, Age=48 Years, Rel Day of Last Recorded Dose of Study Medication=356, PD-L1=PD-L1 Positive, Melanoma Type=Advanced Cutaneous, BRAF=Mutant, NRAS=, c-KIT=											
041013	Treatment Cycle 3	41	Hyperthyroidism	2.96 Months	1	N	Y	None	Resolved	N	
Trial Number=3475-041, Site Number=0012, Subject ID=041009, Gender=Male, Race=Asian, Age=39 Years, Rel Day of Last Recorded Dose of Study Medication=107, PD-L1=PD-L1 Negative, Melanoma Type=Advanced Mucosal, BRAF=Wild Type, NRAS=Undetermined, c-KIT=Undetermined											
041009	Treatment Cycle 2	22	Hyperthyroidism	3.29 Weeks	2	N	Y	None	Resolved	N	
Hypophysitis											
Trial Number=3475-041, Site Number=0003, Subject ID=041024, Gender=Female, Race=Asian, Age=79 Years, Rel Day of Last Recorded Dose of Study Medication=1, PD-L1=Unknown, Melanoma Type=Advanced Cutaneous, BRAF=Wild Type, NRAS=Wild Type, c-KIT=											

C Confidential

付録 2.7.4-63 AEOSI の一覧

041 試験（APaT 集団）（続き）

Subject ID	Onset Epoch	Rel Day of Onset	Adverse Event	Duration	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome	Treated with sysytemic corticosteroid	Starting dose of sysytemic corticosteroid
Hypophysitis											
Trial Number=3475-041, Site Number=0003, Subject ID=041024, Gender=Female, Race=Asian, Age=79 Years, Rel Day of Last Recorded Dose of Study Medication=1, PD-L1=Unknown, Melanoma Type=Advanced Cutaneous, BRAF=Wild Type, NRAS=Wild Type, c-KIT=											
041024	Safety Follow-up	27	Hypopituitarism	Continuing	1	N	N	N/A	Not Resolved	N	
Trial Number=3475-041, Site Number=0012, Subject ID=041011, Gender=Female, Race=Asian, Age=43 Years, Rel Day of Last Recorded Dose of Study Medication=211, PD-L1=PD-L1 Positive, Melanoma Type=Advanced Cutaneous, BRAF=Mutant, NRAS=Undetermined, c-KIT=Undetermined											
041011	Safety Follow-up	220	Hypophysitis	Continuing	2	Y	Y	Discontinued	Not Resolved	N	
Trial Number=3475-041, Site Number=0012, Subject ID=041017, Gender=Male, Race=Asian, Age=56 Years, Rel Day of Last Recorded Dose of Study Medication=333, PD-L1=Unknown, Melanoma Type=Advanced Mucosal, BRAF=Wild Type, NRAS=Undetermined, c-KIT=Undetermined											
041017	Treatment Cycle 12	242	Hypophysitis	Continuing	3	Y	Y	Interrupted	Not Resolved	Y	Low Dose
Hypothyroidism											
Trial Number=3475-041, Site Number=0001, Subject ID=041004, Gender=Male, Race=Asian, Age=66 Years, Rel Day of Last Recorded Dose of Study Medication=376, PD-L1=PD-L1 Positive, Melanoma Type=Advanced Cutaneous, BRAF=Wild Type, NRAS=, c-KIT=											
041004	Treatment Cycle 5	82	Hypothyroidism	Continuing	2	N	Y	None	Not Resolved	N	
Trial Number=3475-041, Site Number=0002, Subject ID=041032, Gender=Male, Race=Asian, Age=57 Years, Rel Day of Last Recorded Dose of Study Medication=261, PD-L1=Unknown, Melanoma Type=Advanced Cutaneous, BRAF=Wild Type, NRAS=Wild Type, c-KIT=											
041032	Treatment Cycle 6	105	Hypothyroidism	Continuing	2	N	Y	None	Not Resolved	N	
Trial Number=3475-041, Site Number=0007, Subject ID=041015, Gender=Male, Race=Asian, Age=65 Years, Rel Day of Last Recorded Dose of Study Medication=338, PD-L1=PD-L1 Negative, Melanoma Type=Advanced Cutaneous, BRAF=Wild Type, NRAS=Undetermined, c-KIT=											

C Confidential

付録 2.7.4-63 AEOSI の一覧

041 試験（APaT 集団）（続き）

Subject ID	Onset Epoch	Rel Day of Onset	Adverse Event	Duration	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome	Treated with sysytemic corticosteroid	Starting dose of sysytemic corticosteroid
Hypothyroidism											
Trial Number=3475-041, Site Number=0007, Subject ID=041015, Gender=Male, Race=Asian, Age=65 Years, Rel Day of Last Recorded Dose of Study Medication=338, PD-L1=PD-L1 Negative, Melanoma Type=Advanced Cutaneous, BRAF=Wild Type, NRAS=Undetermined, c-KIT=											
041015	Treatment Cycle 7	149	Hypothyroidism	Continuing	2	N	Y	Interrupted	Not Resolved	N	
Trial Number=3475-041, Site Number=0007, Subject ID=041025, Gender=Male, Race=Asian, Age=49 Years, Rel Day of Last Recorded Dose of Study Medication=275, PD-L1=PD-L1 Positive, Melanoma Type=Advanced Cutaneous, BRAF=Wild Type, NRAS=Wild Type, c-KIT=											
041025	Treatment Cycle 7	128	Hypothyroidism	Continuing	2	N	Y	None	Not Resolved	N	
Trial Number=3475-041, Site Number=0009, Subject ID=041026, Gender=Female, Race=Asian, Age=84 Years, Rel Day of Last Recorded Dose of Study Medication=59, PD-L1=PD-L1 Negative, Melanoma Type=Advanced Cutaneous, BRAF=Wild Type, NRAS=, c-KIT=											
041026	Safety Follow-up	69	Hypothyroidism	Continuing	1	N	N	N/A	Not Resolved	N	
Infusion Reactions											
Trial Number=3475-041, Site Number=0007, Subject ID=041025, Gender=Male, Race=Asian, Age=49 Years, Rel Day of Last Recorded Dose of Study Medication=275, PD-L1=PD-L1 Positive, Melanoma Type=Advanced Cutaneous, BRAF=Wild Type, NRAS=Wild Type, c-KIT=											
041025	Treatment Cycle 1	1	Cytokine release syndrome	2 Days	2	N	Y	None	Resolved	N	
Trial Number=3475-041, Site Number=0008, Subject ID=041028, Gender=Male, Race=Asian, Age=44 Years, Rel Day of Last Recorded Dose of Study Medication=232, PD-L1=PD-L1 Negative, Melanoma Type=Advanced Cutaneous, BRAF=Undetermined, NRAS=Undetermined, c-KIT=Undetermined											
041028	Treatment Cycle 7	139	Infusion related reaction	2.43 Weeks	1	N	N	None	Resolved	N	
Pneumonitis											

C Confidential

付録 2.7.4-63 AEOSI の一覧

041 試験（APaT 集団）（続き）

Subject ID	Onset Epoch	Rel Day of Onset	Adverse Event	Duration	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome	Treated with sysytemic corticosteroid	Starting dose of sysytemic corticosteroid
Pneumonitis											
Trial Number=3475-041, Site Number=0007, Subject ID=041006, Gender=Male, Race=Asian, Age=69 Years, Rel Day of Last Recorded Dose of Study Medication=63, PD-L1=PD-L1 Positive, Melanoma Type=Advanced Mucosal, BRAF=Wild Type, NRAS=Undetermined, c-KIT=											
041006	Safety Follow-up	84	Pneumonitis	Continuing	2	Y	Y	Discontinued	Resolving	Y	Low Dose
Skin-B											
Trial Number=3475-041, Site Number=0012, Subject ID=041017, Gender=Male, Race=Asian, Age=56 Years, Rel Day of Last Recorded Dose of Study Medication=333, PD-L1=Unknown, Melanoma Type=Advanced Mucosal, BRAF=Wild Type, NRAS=Undetermined, c-KIT=Undetermined											
041017	Treatment Cycle 1	13	Toxic skin eruption	1.02 Months	1	N	Y	None	Resolved	N	
Uveitis											
Trial Number=3475-041, Site Number=0012, Subject ID=041011, Gender=Female, Race=Asian, Age=43 Years, Rel Day of Last Recorded Dose of Study Medication=211, PD-L1=PD-L1 Positive, Melanoma Type=Advanced Cutaneous, BRAF=Mutant, NRAS=Undetermined, c-KIT=Undetermined											
041011	Treatment Cycle 8	158	Uveitis	1.05 Months	2	N	Y	None	Resolved	N	

Action Taken: None = DOSE NOT CHANGED, Reduced = DOSE REDUCED, Interrupted = DRUG INTERRUPTED, Discontinued = DRUG WITHDRAWN, Increased = DOSE INCREASED, N/A = NOT APPLICABLE.

Outcome: Resolved = RECOVERED/RESOLVED, Resolving = RECOVERING/RESOLVING, Sequelae = RECOVERED/RESOLVED WITH SEQUELAE, Not resolved = NOT RECOVERED/NOT RESOLVED.

Related: Investigator-assessed relationship of the adverse event to study medication.

Grades are based on NCI CTCAE version 4.0.

Adverse event terms are from MedDRA Version 18.0.

(Data Cutoff Date: [redacted]).

Data Source: [資料5.3.5.2.3: P041V01]

C Confidential

付録 2.7.4-64 AEOSI-肺臓炎に対する副腎皮質ホルモン剤の使用の要約
041 試験（APaT 集団）

	Subjects With Advanced Melanoma (N=42)	
	n	%
Subjects with one or more Pneumonitis events	1	
Treated with systemic corticosteroid	1	100.0
Not treated with systemic corticosteroid	0	0
The number of Subjects with one or more Pneumonitis events is used as the denominator for the percentage calculation. (Data Cutoff Date: [redacted]).		

Data Source: [資料5.3.5.2.3: P041V01]

Confidential

付録 2.7.4-65 AEOSI-肺臓炎に対する副腎皮質ホルモン剤の用量の要約

041 試験（APaT 集団）

	Subjects With Advanced Melanoma
Total Pneumonitis Episodes	1
High Starting Dose (%) †, n (%)	**0 (0.0)**
Low Starting Dose (%) ‡, n (%)	**1 (100.0)**
Starting dose (mg/day)	
Mean (SD)	30
Median (Range)	30 (30-30)
Duration§ (days)	
Mean (SD)	7
Median (Range)	7 (7-7)
Not Treated with Systemic Corticosteroid, n (%)	**0 (0.0)**

† High starting dose corticosteroid treatment is defined as ≥ 40 mg/day prednisone or equivalent.

§ Low starting dose corticosteroid treatment is defined as < 40 mg/day prednisone or equivalent.

§ Ongoing corticosteroid treatment is censored at the cutoff date or date of death, whichever occurs first.

(Database Cutoff Date: [redacted].

Data Source: [資料5.3.5.2.3: P041V01]

C Confidential

付録 2.7.4-66 AEOSI-肺臓炎に対する副腎皮質ホルモン剤使用の一覧

041 試験（APaT 集団）

Subject ID	Med. Start Day	Med. Duration (Days)	Med. Name	Total Daily Dose	Frequency	Route	Prednisone Equiv.† (mg)	Adverse Event for Use	AE Start Day	AE End Day	AE Toxicity Grade
MK-3475 2 mg/kg Q3W											
Trial Number=3475-041, Site Number=0007, Subject ID=041006, Gender=Male, Race=Asian, Age=69 Years, Rel Day of Study Medication Discontinuance‡=63											
041006	98	7	Prednisolone	30	BID	Oral	30.00	Pneumonitis	84	.	2
	105	6	Prednisolone	10	BID	Oral	10.00	Pneumonitis	84	.	2
	111	9	Prednisolone	10	QD	Intravenous	10.00	Pneumonitis	84	.	2
	120	15	Prednisolone	1	QD	Oral	0.50	Pneumonitis	84	.	2
	135	14	Prednisolone	2	QD	Oral	2.00	Pneumonitis	84	.	2
	149	27	Prednisolone	2	QD	Oral	1.50	Pneumonitis	84	.	2
	176	.	Prednisolone	1	QD	Oral	1.00	Pneumonitis	84	.	2

Med.: Medication.
Equiv.: Equivalent.
AE: Adverse Event.
†: Prednisone equivalent total daily dose.
‡Relative Day of Study Medication Discontinuance is defined as the day of the last recorded dose of study medication for the subject relative to the start of study medication.
AE start date is defined as the start day of the adverse event for the subject relative to the start of study medication.
Grades are based on NCI CTCAE version 4.0.
(Database Cutoff Date: [redacted].

Data Source: [資料5.3.5.2.3: P041V01]

C Confidential

付録 2.7.4-67 AEOSI-大腸炎を発現した患者の一覧

001 試験+002 試験+006 試験（APaT 集団）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 2 mg/kg Q3W										
Trial Number=3475-001, Site Number=0011, Subject ID=000503, Gender=F, Race=White, Age=74 Years, Rel Day of Study Medication Discontinuance†=197										
000503	Treatment Cycle 4	70	Colitis	2.6 Months	Moderate	2	Y	Y	Interrupted	Resolved
	Safety Follow-up	211	Colitis	1.77 Months	Severe	3	Y	Y		Resolved
Trial Number=3475-001, Site Number=0015, Subject ID=000177, Gender=M, Race=White, Age=78 Years, Rel Day of Study Medication Discontinuance†=253										
000177	Safety Follow-up	263	Colitis	4 Days	Severe	3	Y	Y	Discontinued	Resolved
Trial Number=3475-002, Site Number=0080, Subject ID=100910, Gender=F, Race=White, Age=36 Years, Rel Day of Study Medication Discontinuance†=274										
100910	Treatment Cycle 10	191	Colitis	1.38 Months		2	Y	Y	Interrupted	Resolved
Trial Number=3475-002, Site Number=0150, Subject ID=100667, Gender=F, Race=White, Age=56 Years, Rel Day of Study Medication Discontinuance†=										
100667	Treatment Cycle 3	87	Colitis	1.64 Months		2	Y	N	Interrupted	Resolved
MK-3475 10 mg/kg Q3W										
Trial Number=3475-001, Site Number=0011, Subject ID=001327, Gender=M, Race=White, Age=67 Years, Rel Day of Study Medication Discontinuance†=141										
001327	Treatment Cycle 3	80	Colitis	Continuing	Mild	1	Y	N	Interrupted	Not Resolved
Trial Number=3475-001, Site Number=0011, Subject ID=001372, Gender=M, Race=White, Age=53 Years, Rel Day of Study Medication Discontinuance†=208										
001372	Safety Follow-up	222	Colitis	3.29 Weeks	Severe	3	Y	Y	Discontinued	Resolved
Trial Number=3475-001, Site Number=0011, Subject ID=001399, Gender=F, Race=White, Age=56 Years, Rel Day of Study Medication Discontinuance†=										

C Confidential

付録 2.7.4-67 AEOSI-大腸炎を発現した患者の一覧

001 試験+002 試験+006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W										
Trial Number=3475-001, Site Number=0011, Subject ID=001399, Gender=F, Race=White, Age=56 Years, Rel Day of Study Medication Discontinuance†=										
001399	Treatment Cycle 5	107	Colitis	2 Weeks	Severe	3	Y	Y		Resolved
Trial Number=3475-001, Site Number=0021, Subject ID=000476, Gender=M, Race=White, Age=70 Years, Rel Day of Study Medication Discontinuance†=295										
000476	Safety Follow-up	296	Colitis	1.35 Months	Moderate	2	Y	Y	Discontinued	Resolved
Trial Number=3475-002, Site Number=0016, Subject ID=100113, Gender=F, Race=White, Age=61 Years, Rel Day of Study Medication Discontinuance†=										
100113	Treatment Cycle 1	10	Colitis	1.12 Months		2	N	Y	None	Resolved
Trial Number=3475-002, Site Number=0016, Subject ID=100627, Gender=M, Race=White, Age=56 Years, Rel Day of Study Medication Discontinuance†=127										
100627	Safety Follow-up	145	Colitis	3.52 Months		3	N	Y	Discontinued	Resolved
Trial Number=3475-002, Site Number=0053, Subject ID=100661, Gender=M, Race=White, Age=66 Years, Rel Day of Study Medication Discontinuance†=211										
100661	Treatment Cycle 6	123	Colitis	4.3 Months		3	N	Y	Discontinued	Resolved
Trial Number=3475-006, Site Number=0309, Subject ID=363895, Gender=F, Race=White, Age=49 Years, Rel Day of Study Medication Discontinuance†=115										
363895	Treatment Cycle 5	96	Colitis	23 Hours		3	N	Y	Interrupted	Resolved
Trial Number=3475-006, Site Number=0701, Subject ID=360019, Gender=M, Race=White, Age=66 Years, Rel Day of Study Medication Discontinuance†=64										
360019	Treatment Cycle 3	57	Colitis	3.94 Months		3	Y	Y	Discontinued	Resolved
Trial Number=3475-006, Site Number=1201, Subject ID=368020, Gender=F, Race=White, Age=69 Years, Rel Day of Study Medication Discontinuance†=										

C Confidential

付録 2.7.4-67 AEOSI-大腸炎を発現した患者の一覧

001 試験+002 試験+006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W										
Trial Number=3475-006, Site Number=1201, Subject ID=368020, Gender=F, Race=White, Age=69 Years, Rel Day of Study Medication Discontinuance†=										
368020	Treatment Cycle 6	125	Colitis	Continuing		3	N	N	None	Not Resolved
Trial Number=3475-006, Site Number=1402, Subject ID=368856, Gender=M, Race=White, Age=61 Years, Rel Day of Study Medication Discontinuance†=85										
368856	Treatment Cycle 3	54	Colitis	6.57 Months		1	Y	Y	None	Resolved
Trial Number=3475-006, Site Number=1500, Subject ID=363996, Gender=M, Race=White, Age=42 Years, Rel Day of Study Medication Discontinuance†=22										
363996	Safety Follow-up	37	Colitis	1.64 Months		2	Y	Y	Discontinued	Resolved
Trial Number=3475-006, Site Number=1601, Subject ID=364335, Gender=M, Race=White, Age=70 Years, Rel Day of Study Medication Discontinuance†=45										
364335	Treatment Cycle 2	41	Colitis	1.41 Months		4	Y	Y	Discontinued	Resolved
Trial Number=3475-006, Site Number=1804, Subject ID=364357, Gender=F, Race=White, Age=57 Years, Rel Day of Study Medication Discontinuance†=182										
364357	Treatment Cycle 7	134	Colitis	1.51 Months		2	N	Y	Interrupted	Resolved
Trial Number=3475-006, Site Number=1809, Subject ID=361785, Gender=F, Race=White, Age=65 Years, Rel Day of Study Medication Discontinuance†=										
361785	Treatment Cycle 4	73	Colitis	6 Days		3	Y	N	None	Resolved
Trial Number=3475-006, Site Number=1815, Subject ID=360878, Gender=M, Race=White, Age=78 Years, Rel Day of Study Medication Discontinuance†=63										
360878	Treatment Cycle 3	46	Colitis	6.34 Months		4	Y	Y	Discontinued	Resolved
Trial Number=3475-006, Site Number=1816, Subject ID=364466, Gender=M, Race=White, Age=71 Years, Rel Day of Study Medication Discontinuance†=250										

C Confidential

付録 2.7.4-67 AEOSI-大腸炎を発現した患者の一覧

001 試験+002 試験+006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W										
Trial Number=3475-006, Site Number=1816, Subject ID=364466, Gender=M, Race=White, Age=71 Years, Rel Day of Study Medication Discontinuance†=250										
364466	Treatment Cycle 7	128	Colitis	2 Weeks		2	N	Y	None	Resolved
	Treatment Cycle 8	160	Colitis	1.14 Weeks		2	N	Y	None	Resolved
	Treatment Cycle 9	186	Colitis	1.12 Months		2	N	Y	None	Resolved
	Safety Follow-up	259	Colitis	3.86 Weeks		3	N	Y	Discontinued	Resolved
MK-3475 10 mg/kg Q2W										
Trial Number=3475-001, Site Number=0001, Subject ID=001218, Gender=M, Race=White, Age=47 Years, Rel Day of Study Medication Discontinuance†=183										
001218	Treatment Cycle 7	103	Colitis	4 Weeks	Moderate	2		Y	Interrupted	Resolved
Trial Number=3475-001, Site Number=0010, Subject ID=000031, Gender=M, Race=White, Age=77 Years, Rel Day of Study Medication Discontinuance†=										
000031	Treatment Cycle 10	130	Colitis microscopic	3.61 Months	Mild	1	Y	Y		Resolved
Trial Number=3475-001, Site Number=0011, Subject ID=001340, Gender=M, Race=White, Age=62 Years, Rel Day of Study Medication Discontinuance†=83										
001340	Safety Follow-up	95	Colitis	1.45 Months	Severe	3	Y	Y	Interrupted	Resolved
Trial Number=3475-001, Site Number=0015, Subject ID=001267, Gender=M, Race=White, Age=50 Years, Rel Day of Study Medication Discontinuance†=										
001267	Treatment Cycle 13	223	Colitis	4 Days	Severe	3	Y	N		Resolved
Trial Number=3475-001, Site Number=0018, Subject ID=001308, Gender=F, Race=White, Age=38 Years, Rel Day of Study Medication Discontinuance†=165										
001308	Treatment Cycle 13	165	Enterocolitis	1.86 Weeks	Severe	3	Y	Y	Discontinued	Resolved

C Confidential

付録 2.7.4-67 AEOSI-大腸炎を発現した患者の一覧

001 試験+002 試験+006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q2W										
Trial Number=3475-006, Site Number=0301, Subject ID=362932, Gender=M, Race=White, Age=32 Years, Rel Day of Study Medication Discontinuance†=										
362932	Treatment Cycle 6	78	Colitis	17.05 Hours		3	Y	Y	None	Resolved
Trial Number=3475-006, Site Number=0605, Subject ID=360713, Gender=M, Race=White, Age=66 Years, Rel Day of Study Medication Discontinuance†=153										
360713	Treatment Cycle 9	125	Colitis	2.5 Months		3	Y	Y	Discontinued	Resolved
Trial Number=3475-006, Site Number=0605, Subject ID=362930, Gender=M, Race=White, Age=59 Years, Rel Day of Study Medication Discontinuance†=85										
362930	Safety Follow-up	87	Colitis	1.12 Months		3	Y	Y	Discontinued	Resolved
Trial Number=3475-006, Site Number=1705, Subject ID=365415, Gender=F, Race=White, Age=66 Years, Rel Day of Study Medication Discontinuance†=197										
365415	Treatment Cycle 6	72	Colitis	2.57 Weeks		2	N	Y	None	Resolved
	Safety Follow-up	204	Colitis	Continuing		3	Y	Y	Discontinued	Not Resolved
Trial Number=3475-006, Site Number=1808, Subject ID=366961, Gender=F, Race=White, Age=79 Years, Rel Day of Study Medication Discontinuance†=141										

C Confidential

付録 2.7.4-67 AEOSI-大腸炎を発現した患者の一覧

001 試験+002 試験+006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q2W										
Trial Number=3475-006, Site Number=1808, Subject ID=366961, Gender=F, Race=White, Age=79 Years, Rel Day of Study Medication Discontinuance[†]=141										
366961	Safety Follow-up	148	Colitis microscopic	Continuing		2	N	Y	None	Not Resolved

[†]Relative Day of Study Medication Discontinuance is defined as the day of the last recorded dose of study medication for the subject relative to the start of study medication.

Action Taken: None = DOSE NOT CHANGED, Reduced = DOSE REDUCED, Interrupted = DRUG INTERRUPTED, Discontinued = DRUG WITHDRAWN, Increased = DOSE INCREASED, N/A = NOT APPLICABLE.

Outcome: Resolved = RECOVERED/RESOLVED, Resolving = RECOVERING/RESOLVING, Sequelae = RECOVERED/RESOLVED WITH SEQUELAE, Not resolved = NOT RECOVERED/NOT RESOLVED.

Related: Investigator-assessed relationship of the adverse event to study medication.

Grades are based on NCI CTCAE version 4.0.

(MK-3475 PN001 Database Cutoff Date: [redacted]).

(MK-3475 PN002 Database Cutoff Date: 12MAY2014).

(MK-3475 PN006 Database Cutoff Date: 03SEP2014).

Confidential

付録 2.7.4-68 AEOSI-大腸炎に対する副腎皮質ホルモン剤使用の一覧

001 試験+002 試験+006 試験（APaT 集団）

Subject ID	Med. Start Day	Med. Duration (Days)	Med. Name	Total Daily Dose	Frequency	Route	Prednisone Equiv.† (mg)	Adverse Event for Use	AE Start Day	AE End Day	AE Toxicity Grade
MK-3475 2 mg/kg Q3W											
Trial Number=3475-001, Site Number=0011, Subject ID=000503, Gender=F, Race=White, Age=74 Years, Rel Day of Study Medication Discontinuance‡=197											
000503	114	4	Prednisone	60	QD	Oral Administration	60.00	Colitis	70	148	2
	119	5	Prednisone	40	QD	Oral Administration	40.00	Colitis	70	148	2
	124	5	Prednisone	30	QD	Oral Administration	30.00	Colitis	70	148	2
	129	15	Prednisone	20	QD	Oral Administration	20.00	Colitis	70	148	2
Trial Number=3475-002, Site Number=0080, Subject ID=100910, Gender=F, Race=White, Age=36 Years, Rel Day of Study Medication Discontinuance‡=274											
100910	212	6	Methylprednisolone	60	QD	Oral	75.00	Colitis	191	232	2
	218	4	Methylprednisolone	30	QD	Oral	37.50	Colitis	191	232	2
	222	4	Methylprednisolone	10	QD	Oral	12.50	Colitis	191	232	2
	226	4	Methylprednisolone	4	QD	Oral	5.00	Colitis	191	232	2
	230	3	Methylprednisolone	2	QD	Oral	2.50	Colitis	191	232	2
	250	7	Methylprednisolone	60	QD	Oral	75.00	Colitis	191	232	2
	257	7	Methylprednisolone	40	QD	Oral	50.00	Colitis	191	232	2
	264	5	Methylprednisolone	30	QD	Oral	37.50	Colitis	191	232	2
	269	5	Methylprednisolone	16	QD	Oral	20.00	Colitis	191	232	2
	274	7	Methylprednisolone	8	QD	Oral	10.00	Colitis	191	232	2

C Confidential

付録 2.7.4-68 AEOSI-大腸炎に対する副腎皮質ホルモン剤使用の一覧

001 試験+002 試験+006 試験（APaT 集団）（続き）

Subject ID	Med. Start Day	Med. Duration (Days)	Med. Name	Total Daily Dose	Frequency	Route	Prednisone Equiv.† (mg)	Adverse Event for Use	AE Start Day	AE End Day	AE Toxicity Grade
	281	.	Methylprednisolone	6	QD	Oral	7.50	Colitis	191	232	2
MK-3475 10 mg/kg Q3W											
Trial Number=3475-001, Site Number=0011, Subject ID=001372, Gender=M, Race=White, Age=53 Years, Rel Day of Study Medication Discontinuance‡=208											
001372	222	3	Methylprednisolone	80	BID	Intravenous Administration	100.00	Colitis	222	244	3
	224	.	Prednisone	80	BID	Oral Administration	80.00	Colitis	222	244	3
Trial Number=3475-001, Site Number=0011, Subject ID=001399, Gender=F, Race=White, Age=56 Years, Rel Day of Study Medication Discontinuance‡=											
001399	110	.	Prednisone	60	QD	Oral Administration	60.00	Colitis	107	120	3
Trial Number=3475-001, Site Number=0021, Subject ID=000476, Gender=M, Race=White, Age=70 Years, Rel Day of Study Medication Discontinuance‡=295											
000476	296	41	Prednisolone	120	BID	Oral Administration	120.00	Colitis	296	336	2
Trial Number=3475-002, Site Number=0016, Subject ID=100627, Gender=M, Race=White, Age=56 Years, Rel Day of Study Medication Discontinuance‡=127											
100627	145	10	Prednisone	50	OTHER	Oral	50.00	Colitis	145	251	3
Trial Number=3475-002, Site Number=0053, Subject ID=100661, Gender=M, Race=White, Age=66 Years, Rel Day of Study Medication Discontinuance‡=211											
100661	228	19	Prednisone	40	QD	Oral	40.00	Colitis	123	253	3
	253	14	Prednisone	30	QD	Oral	30.00	Colitis	123	253	3
	267	14	Prednisone	20	QD	Oral	20.00	Colitis	123	253	3
Trial Number=3475-006, Site Number=0309, Subject ID=363895, Gender=F, Race=White, Age=49 Years, Rel Day of Study Medication Discontinuance‡=115											
363895	96	4	Dexamethasone	20	QD	Intravenous	133.40	Colitis	96	.	3

C Confidential

付録 2.7.4-68 AEOSI-大腸炎に対する副腎皮質ホルモン剤使用の一覧

001 試験+002 試験+006 試験（APaT 集団）（続き）

Subject ID	Med. Start Day	Med. Duration (Days)	Med. Name	Total Daily Dose	Frequency	Route	Prednisone Equiv.† (mg)	Adverse Event for Use	AE Start Day	AE End Day	AE Toxicity Grade
Trial Number=3475-006, Site Number=0701, Subject ID=360019, Gender=M, Race=White, Age=66 Years, Rel Day of Study Medication Discontinuance†=64											
360019	85	8	Methylprednisolone	280	QD	Intravenous	350.00	Colitis	57	176	3
	96	25	Methylprednisolone	150	QD	Oral	187.50	Colitis	57	176	3
	120	4	Methylprednisolone	140	QD	Intravenous	175.00	Colitis	57	176	3
	124	24	Methylprednisolone	80	QD	Oral	100.00	Colitis	57	176	3
	148	15	Methylprednisolone	40	QD	Oral	50.00	Colitis	57	176	3
	163	14	Methylprednisolone	20	QD	Oral	25.00	Colitis	57	176	3
	79	7	Prednisolone	140	QD	Oral	140.00	Colitis	57	176	3
Trial Number=3475-006, Site Number=1402, Subject ID=368856, Gender=M, Race=White, Age=61 Years, Rel Day of Study Medication Discontinuance†=85											
368856	106	3	Methylprednisolone	32	BID	Oral	40.00	Colitis	54	.	1
	109	3	Methylprednisolone	28	BID	Oral	35.00	Colitis	54	.	1
	112	3	Methylprednisolone	24	BID	Oral	30.00	Colitis	54	.	1
	115	3	Methylprednisolone	20	BID	Oral	25.00	Colitis	54	.	1
	118	3	Methylprednisolone	16	BID	Oral	20.00	Colitis	54	.	1
	121	3	Methylprednisolone	12	BID	Oral	15.00	Colitis	54	.	1
	124	3	Methylprednisolone	8	QD	Oral	10.00	Colitis	54	.	1
	127	3	Methylprednisolone	4	QD	Oral	5.00	Colitis	54	.	1

C Confidential

付録 2.7.4-68 AEOSI-大腸炎に対する副腎皮質ホルモン剤使用の一覧

001 試験+002 試験+006 試験（APaT 集団）（続き）

Subject ID	Med. Start Day	Med. Duration (Days)	Med. Name	Total Daily Dose	Frequency	Route	Prednisone Equiv.[†] (mg)	Adverse Event for Use	AE Start Day	AE End Day	AE Toxicity Grade
	134	3	Methylprednisolone	8	BID	Oral	10.00	Colitis	54	.	1
	137	1	Methylprednisolone	4	QD	Oral	5.00	Colitis	54	.	1
	138	28	Methylprednisolone	8	BID	Oral	10.00	Colitis	54	.	1
Trial Number=3475-006, Site Number=1500, Subject ID=363996, Gender=M, Race=White, Age=42 Years, Rel Day of Study Medication Discontinuance[‡]=22											
363996	50	10	Methylprednisolone	60	QD	Intravenous	75.00	Colitis	37	86	2
	60	4	Methylprednisolone	60	QD	Oral	75.00	Colitis	37	86	2
	64	7	Methylprednisolone	50	QD	Oral	62.50	Colitis	37	86	2
	71	7	Methylprednisolone	40	QD	Oral	50.00	Colitis	37	86	2
	78	7	Methylprednisolone	30	QD	Oral	37.50	Colitis	37	86	2
	85	3	Methylprednisolone	20	QD	Oral	25.00	Colitis	37	86	2
Trial Number=3475-006, Site Number=1601, Subject ID=364335, Gender=M, Race=White, Age=70 Years, Rel Day of Study Medication Discontinuance[‡]=45											
364335	58	7	Methylprednisolone Sodium Succinate	188	QD	Intravenous	234.38	Colitis	41	83	4
	64	7	Prednisolone	10	QD	Oral	10.00	Colitis	41	83	4
	64	38	Prednisolone	10	QD	Oral	10.00	Colitis	41	83	4
Trial Number=3475-006, Site Number=1804, Subject ID=364357, Gender=F, Race=White, Age=57 Years, Rel Day of Study Medication Discontinuance[‡]=182											
364357	148	8	Prednisone	40	QD	Oral	40.00	Colitis	134	179	2
	156	5	Prednisone	20	QD	Oral	20.00	Colitis	134	179	2

Confidential

付録 2.7.4-68 AEOSI-大腸炎に対する副腎皮質ホルモン剤使用の一覧

001 試験+002 試験+006 試験（APaT 集団）（続き）

Subject ID	Med. Start Day	Med. Duration (Days)	Med. Name	Total Daily Dose	Frequency	Route	Prednisone Equiv.† (mg)	Adverse Event for Use	AE Start Day	AE End Day	AE Toxicity Grade
Trial Number=3475-006, Site Number=1815, Subject ID=360878, Gender=M, Race=White, Age=78 Years, Rel Day of Study Medication Discontinuance‡=63											
360878	143	2	Methylprednisolone Sodium Succinate	.		Intravenous	.	Colitis	46	238	4
	72	3	Prednisone	80	BID	Oral	80.00	Colitis	46	238	4
	75	6	Prednisone	50	QD	Oral	50.00	Colitis	46	238	4
	81	7	Prednisone	30	QD	Oral	30.00	Colitis	46	238	4
	88	9	Prednisone	15	QD	Oral	15.00	Colitis	46	238	4
	144	15	Prednisone	70	QD	Oral	70.00	Colitis	46	238	4
	159	17	Prednisone	60	QD	Oral	60.00	Colitis	46	238	4
	176	5	Prednisone	40	QD	Oral	40.00	Colitis	46	238	4
	181	7	Prednisone	20	QD	Oral	20.00	Colitis	46	238	4
	188	7	Prednisone	10	QD	Oral	10.00	Colitis	46	238	4
	195	8	Prednisone	5	QD	Oral	5.00	Colitis	46	238	4
	203	7	Prednisone	5	QOD	Oral	5.00	Colitis	46	238	4
Trial Number=3475-006, Site Number=1816, Subject ID=364466, Gender=M, Race=White, Age=71 Years, Rel Day of Study Medication Discontinuance‡=250											
364466	271	1	Dexamethasone Sodium Phosphate	20	1 TIME PER WEEK	Intravenous	133.40	Colitis	259	285	3
	164	6	Prednisone	20	QD	Oral	20.00	Colitis	160	167	2
	205	12	Prednisone	40	BID	Oral	40.00	Colitis	186	219	2

Confidential

付録 2.7.4-68 AEOSI-大腸炎に対する副腎皮質ホルモン剤使用の一覧

001 試験+002 試験+006 試験（APaT 集団）（続き）

Subject ID	Med. Start Day	Med. Duration (Days)	Med. Name	Total Daily Dose	Frequency	Route	Prednisone Equiv.† (mg)	Adverse Event for Use	AE Start Day	AE End Day	AE Toxicity Grade
	272	.	Prednisone	80	QD	Oral	80.00	Colitis	259	285	3
MK-3475 10 mg/kg Q2W											
Trial Number=3475-001, Site Number=0001, Subject ID=001218, Gender=M, Race=White, Age=47 Years, Rel Day of Study Medication Discontinuance‡=183											
001218	103	7	Prednisone	40	QD	Oral Administration	40.00	Colitis	103	130	2
	110	7	Prednisone	30	QD	Oral Administration	30.00	Colitis	103	130	2
	117	32	Prednisone	10	QD	Oral Administration	10.00	Colitis	103	130	2
Trial Number=3475-001, Site Number=0011, Subject ID=001340, Gender=M, Race=White, Age=62 Years, Rel Day of Study Medication Discontinuance‡=83											
001340	95	5	Prednisone	60	QD	Oral Administration	60.00	Colitis	95	138	3
Trial Number=3475-001, Site Number=0018, Subject ID=001308, Gender=F, Race=White, Age=38 Years, Rel Day of Study Medication Discontinuance‡=165											
001308	170	5	Prednisone	70	QD	Oral Administration	70.00	Enterocolitis	165	177	3
	175	5	Prednisone	60	QD	Oral Administration	60.00	Enterocolitis	165	177	3
	180	5	Prednisone	50	QD	Oral Administration	50.00	Enterocolitis	165	177	3
	185	5	Prednisone	40	QD	Oral Administration	40.00	Enterocolitis	165	177	3
	190	5	Prednisone	30	QD	Oral Administration	30.00	Enterocolitis	165	177	3
	195	5	Prednisone	20	QD	Oral Administration	20.00	Enterocolitis	165	177	3
	200	5	Prednisone	10	QD	Oral Administration	10.00	Enterocolitis	165	177	3
Trial Number=3475-006, Site Number=0605, Subject ID=360713, Gender=M, Race=White, Age=66 Years, Rel Day of Study Medication Discontinuance‡=153											

C Confidential

付録 2.7.4-68 AEOSI-大腸炎に対する副腎皮質ホルモン剤使用の一覧

001 試験+002 試験+006 試験（APaT 集団）（続き）

Subject ID	Med. Start Day	Med. Duration (Days)	Med. Name	Total Daily Dose	Frequency	Route	Prednisone Equiv.[†] (mg)	Adverse Event for Use	AE Start Day	AE End Day	AE Toxicity Grade
360713	184	1	Methylprednisolone Sodium Succinate	60	QD	Intravenous	75.00	Colitis	125	200	3
	185	3	Methylprednisolone Sodium Succinate	120	QD	Intravenous	150.00	Colitis	125	200	3
	188	1	Methylprednisolone Sodium Succinate	60	QD	Intravenous	75.00	Colitis	125	200	3
	189	21	Prednisone	60	QD	Oral	60.00	Colitis	125	200	3
	210	7	Prednisone	50	QD	Oral	50.00	Colitis	125	200	3
	217	7	Prednisone	40	QD	Oral	40.00	Colitis	125	200	3
Trial Number=3475-006, Site Number=0605, Subject ID=362930, Gender=M, Race=White, Age=59 Years, Rel Day of Study Medication Discontinuance[‡]=85											
362930	101	6	Methylprednisolone Sodium Succinate	60	QD	Intravenous	75.00	Colitis	87	120	3
	107	15	Prednisolone Sodium Metazoate	80	BID	Oral	80.00	Colitis	87	120	3
	122	11	Prednisolone Sodium Metazoate	60	QD	Oral	60.00	Colitis	87	120	3
	133	11	Prednisolone Sodium Metazoate	50	QD	Oral	50.00	Colitis	87	120	3
	144	10	Prednisolone Sodium Metazoate	40	QD	Oral	40.00	Colitis	87	120	3
	154	11	Prednisolone Sodium Metazoate	30	QD	Oral	30.00	Colitis	87	120	3
	165	11	Prednisolone Sodium Metazoate	20	QD	Oral	20.00	Colitis	87	120	3
	176	10	Prednisolone Sodium Metazoate	15	QD	Oral	15.00	Colitis	87	120	3
	186	11	Prednisolone Sodium Metazoate	10	QD	Oral	10.00	Colitis	87	120	3
	197	11	Prednisolone Sodium Metazoate	5	QD	Oral	5.00	Colitis	87	120	3

C Confidential

付録 2.7.4-68 AEOSI-大腸炎に対する副腎皮質ホルモン剤使用の一覧

001 試験+002 試験+006 試験（APaT 集団）（続き）

Subject ID	Med. Start Day	Med. Duration (Days)	Med. Name	Total Daily Dose	Frequency	Route	Prednisone Equiv.† (mg)	Adverse Event for Use	AE Start Day	AE End Day	AE Toxicity Grade
Trial Number=3475-006, Site Number=1705, Subject ID=365415, Gender=F, Race=White, Age=66 Years, Rel Day of Study Medication Discontinuance‡=197											
365415	213	2	Prednisolone	55	QD	Oral	55.00	Colitis	204	.	3
	215	3	Prednisolone	60	QD	Oral	60.00	Colitis	204	.	3
	218	5	Prednisolone	40	QD	Oral	40.00	Colitis	204	.	3
	223	5	Prednisolone	30	QD	Oral	30.00	Colitis	204	.	3
	228	5	Prednisolone	20	QD	Oral	20.00	Colitis	204	.	3
	233	5	Prednisolone	10	QD	Oral	10.00	Colitis	204	.	3

付録 2.7.4-68 AEOSI-大腸炎に対する副腎皮質ホルモン剤使用の一覧

001 試験+002 試験+006 試験（APaT 集団）（続き）

Subject ID	Med. Start Day	Med. Duration (Days)	Med. Name	Total Daily Dose	Frequency	Route	Prednisone Equiv.† (mg)	Adverse Event for Use	AE Start Day	AE End Day	AE Toxicity Grade
	238	6	Prednisolone	5	QD	Oral	5.00	Colitis	204	.	3
	248	5	Prednisolone	30	QD	Oral	30.00	Colitis	204	.	3
	253	5	Prednisolone	15	QD	Oral	15.00	Colitis	204	.	3
	258	5	Prednisolone	5	QD	Oral	5.00	Colitis	204	.	3
	269	2	Prednisolone	25	QD	Oral	25.00	Colitis	204	.	3
	271	6	Prednisolone	30	QD	Oral	30.00	Colitis	204	.	3
	277	5	Prednisolone	100	QD	Oral	100.00	Colitis	204	.	3

C Confidential

付録 2.7.4-68 AEOSI-大腸炎に対する副腎皮質ホルモン剤使用の一覧

001 試験+002 試験+006 試験（APaT 集団）（続き）

Subject ID	Med. Start Day	Med. Duration (Days)	Med. Name	Total Daily Dose	Frequency	Route	Prednisone Equiv.[†] (mg)	Adverse Event for Use	AE Start Day	AE End Day	AE Toxicity Grade
	282	5	Prednisolone	90	QD	Oral	90.00	Colitis	204	.	3
	287	5	Prednisolone	80	QD	Oral	80.00	Colitis	204	.	3

Med.: Medication.
Equiv.: Equivalent.
AE: Adverse Event.
[†]: Prednisone equivalent total daily dose.
[‡]Relative Day of Study Medication Discontinuance is defined as the day of the last recorded dose of study medication for the subject relative to the start of study medication.
AE start date is defined as the start day of the adverse event for the subject relative to the start of study medication.
Grades are based on NCI CTCAE version 4.0.
(MK-3475 PN001 Database Cutoff Date [redacted].
(MK-3475 PN002 Database Cutoff Date: 12MAY2014).
(MK-3475 PN006 Database Cutoff Date: 03SEP2014).

C Confidential

付録 2.7.4-69 AEOSI-大腸炎に対する副腎皮質ホルモン剤使用の一覧

041 試験（APaT 集団）

Subject ID	Med. Start Day	Med. Duration (Days)	Med. Name	Total Daily Dose	Frequency	Route	Prednisone Equiv.† (mg)	Adverse Event for Use	AE Start Day	AE End Day	AE Toxicity Grade
MK-3475 2 mg/kg Q3W											
Trial Number=3475-041, Site Number=0001, Subject ID=041001, Gender=Male, Race=Asian, Age=67 Years											
041001	139	7	Prednisolone	60	BID	Oral	60.00	Colitis	137	196	3
	146	2	Prednisolone	50	BID	Oral	50.00	Colitis	137	196	3
	148	4	Prednisolone	40	BID	Oral	40.00	Colitis	137	196	3
	152	7	Prednisolone	30	BID	Oral	30.00	Colitis	137	196	3
	159	5	Prednisolone	25	BID	Oral	25.00	Colitis	137	196	3
	164	5	Prednisolone	20	QD	Oral	20.00	Colitis	137	196	3
	169	5	Prednisolone	15	QD	Oral	15.00	Colitis	137	196	3
	174	5	Prednisolone	10	QD	Oral	10.00	Colitis	137	196	3

Confidential

付録 2.7.4-69 AEOSI-大腸炎に対する副腎皮質ホルモン剤使用の一覧

041 試験（APaT 集団）（続き）

Subject ID	Med. Start Day	Med. Duration (Days)	Med. Name	Total Daily Dose	Frequency	Route	Prednisone Equiv.[†] (mg)	Adverse Event for Use	AE Start Day	AE End Day	AE Toxicity Grade
	179	5	Prednisolone	5	QD	Oral	5.00	Colitis	137	196	3
Trial Number=3475-041, Site Number=0007, Subject ID=041025, Gender=Male, Race=Asian, Age=49 Years											
041025	280	15	Prednisolone	30	BID	Oral	30.00	Colitis	276	.	2
	295	11	Prednisolone	40	BID	Oral	40.00	Colitis	276	.	2
	306	8	Prednisolone	30	BID	Oral	30.00	Colitis	276	.	2
	314	.	Prednisolone	20	BID	Oral	20.00	Colitis	276	.	2

Med.: Medication.
Equiv.: Equivalent.
AE: Adverse Event.
[†]: Prednisone equivalent total daily dose.
[‡]Relative Day of Study Medication Discontinuance is defined as the day of the last recorded dose of study medication for the subject relative to the start of study medication.
AE start date is defined as the start day of the adverse event for the subject relative to the start of study medication.
Grades are based on NCI CTCAE version 4.0.
(Data Cutoff Date: [redacted].

Data Source: [資料5.3.5.2.3: P041V01]

C Confidential

付録 2.7.4-70 AEOSI-甲状腺機能低下症を発現した患者の一覧

001 試験+002 試験+006 試験（APaT 集団）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 2 mg/kg Q3W										
Trial Number=3475-001, Site Number=0010, Subject ID=000157, Gender=M, Race=White, Age=32 Years, Rel Day of Study Medication Discontinuance†=147										
000157	Treatment Cycle 4	68	Hypothyroidism	Continuing	Moderate	2		Y		Not Resolved
Trial Number=3475-001, Site Number=0010, Subject ID=000282, Gender=M, Race=White, Age=55 Years, Rel Day of Study Medication Discontinuance†=315										
000282	Treatment Cycle 10	189	Hypothyroidism	Continuing	Moderate	2		Y		Not Resolved
Trial Number=3475-001, Site Number=0010, Subject ID=000295, Gender=M, Race=White, Age=47 Years, Rel Day of Study Medication Discontinuance†=64										
000295	Safety Follow-up	70	Hypothyroidism	2 Weeks	Moderate	2		Y		Resolved
Trial Number=3475-001, Site Number=0010, Subject ID=000457, Gender=M, Race=White, Age=61 Years, Rel Day of Study Medication Discontinuance†=43										
000457	Safety Follow-up	48	Hypothyroidism	6 Days	Mild	1		Y	N/A	Resolved
		54	Hypothyroidism	Continuing	Moderate	2		Y		Not Resolved
Trial Number=3475-001, Site Number=0011, Subject ID=000307, Gender=M, Race=White, Age=88 Years, Rel Day of Study Medication Discontinuance†=										
000307	Treatment Cycle 17	362	Hypothyroidism	Continuing	Moderate	2		Y		Not Resolved
Trial Number=3475-001, Site Number=0011, Subject ID=000498, Gender=M, Race=White, Age=54 Years, Rel Day of Study Medication Discontinuance†=										
000498	Treatment Cycle 4	65	Hypothyroidism	Continuing	Mild	1		Y		Not Resolved
Trial Number=3475-001, Site Number=0015, Subject ID=000491, Gender=M, Race=White, Age=65 Years, Rel Day of Study Medication Discontinuance†=										
000491	Treatment Cycle 4	62	Hypothyroidism	Continuing	Moderate	2		Y		Not Resolved

C Confidential

付録 2.7.4-70 AEOSI-甲状腺機能低下症を発現した患者の一覧

001 試験+002 試験+006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 2 mg/kg Q3W										
Trial Number=3475-001, Site Number=0018, Subject ID=000409, Gender=M, Race=White, Age=80 Years, Rel Day of Study Medication Discontinuance†=272										
000409	Treatment Cycle 4	62	Hypothyroidism	Continuing	Moderate	2		Y		Not Resolved
Trial Number=3475-001, Site Number=0018, Subject ID=000466, Gender=M, Race=White, Age=71 Years, Rel Day of Study Medication Discontinuance†=										
000466	Treatment Cycle 9	186	Hypothyroidism	Continuing	Moderate	2		Y		Not Resolved
Trial Number=3475-001, Site Number=0020, Subject ID=000550, Gender=F, Race=White, Age=52 Years, Rel Day of Study Medication Discontinuance†=176										
000550	Treatment Cycle 6	106	Hypothyroidism	Continuing	Moderate	2		Y		Not Resolved
Trial Number=3475-001, Site Number=0021, Subject ID=000528, Gender=F, Race=White, Age=55 Years, Rel Day of Study Medication Discontinuance†=										
000528	Treatment Cycle 2	38	Hypothyroidism	Continuing	Moderate	2		Y		Not Resolved
Trial Number=3475-001, Site Number=0021, Subject ID=000538, Gender=F, Race=White, Age=36 Years, Rel Day of Study Medication Discontinuance†=64										
000538	Treatment Cycle 2	22	Hypothyroidism	Continuing	Moderate	2		Y		Not Resolved
Trial Number=3475-001, Site Number=0021, Subject ID=000545, Gender=M, Race=White, Age=66 Years, Rel Day of Study Medication Discontinuance†=										
000545	Treatment Cycle 10	189	Hypothyroidism	Continuing	Moderate	2		Y		Not Resolved
Trial Number=3475-001, Site Number=0023, Subject ID=000320, Gender=F, Race=White, Age=57 Years, Rel Day of Study Medication Discontinuance†=										
000320	Treatment Cycle 13	253	Hypothyroidism	Continuing	Moderate	2		Y		Not Resolved
Trial Number=3475-002, Site Number=0007, Subject ID=101234, Gender=M, Race=White, Age=78 Years, Rel Day of Study Medication Discontinuance†=										

C Confidential

付録 2.7.4-70 AEOSI-甲状腺機能低下症を発現した患者の一覧

001 試験+002 試験+006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 2 mg/kg Q3W										
Trial Number=3475-002, Site Number=0007, Subject ID=101234, Gender=M, Race=White, Age=78 Years, Rel Day of Study Medication Discontinuance†=										
101234	Treatment Cycle 14	296	Hypothyroidism	Continuing		1	N	Y	None	Not Resolved
Trial Number=3475-002, Site Number=0010, Subject ID=100677, Gender=F, Race=White, Age=76 Years, Rel Day of Study Medication Discontinuance†=252										
100677	Treatment Cycle 1	22	Hypothyroidism	Continuing		2	N	Y	None	Not Resolved
Trial Number=3475-002, Site Number=0016, Subject ID=100619, Gender=M, Race=White, Age=75 Years, Rel Day of Study Medication Discontinuance†=255										
100619	Treatment Cycle 6	106	Hypothyroidism	Continuing		2	N	Y	None	Not Resolved
Trial Number=3475-002, Site Number=0031, Subject ID=101270, Gender=M, Race=White, Age=77 Years, Rel Day of Study Medication Discontinuance†=85										
101270	Safety Follow-up	115	Hypothyroidism	Continuing		2	N	Y	N/A	Not Resolved
Trial Number=3475-002, Site Number=0033, Subject ID=100325, Gender=F, Race=White, Age=49 Years, Rel Day of Study Medication Discontinuance†=										
100325	Treatment Cycle 5	106	Hypothyroidism	Continuing		2	N	Y	None	Not Resolved
Trial Number=3475-002, Site Number=0058, Subject ID=100041, Gender=F, Race=White, Age=39 Years, Rel Day of Study Medication Discontinuance†=										
100041	Treatment Cycle 4	84	Hypothyroidism	Continuing		2	N	Y	None	Not Resolved
Trial Number=3475-002, Site Number=0061, Subject ID=101204, Gender=F, Race=White, Age=43 Years, Rel Day of Study Medication Discontinuance†=										
101204	Treatment Cycle 18	371	Hypothyroidism	Continuing		2	N	Y	None	Not Resolved
Trial Number=3475-002, Site Number=0081, Subject ID=100664, Gender=M, Race=White, Age=15 Years, Rel Day of Study Medication Discontinuance†=148										

C Confidential

付録 2.7.4-70 AEOSI-甲状腺機能低下症を発現した患者の一覧

001 試験+002 試験+006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 2 mg/kg Q3W										
Trial Number=3475-002, Site Number=0081, Subject ID=100664, Gender=M, Race=White, Age=15 Years, Rel Day of Study Medication Discontinuance†=148										
100664	Treatment Cycle 3	42	Hypothyroidism	3.14 Weeks		1	N	N	None	Resolved
Trial Number=3475-002, Site Number=0087, Subject ID=102107, Gender=M, Race=White, Age=34 Years, Rel Day of Study Medication Discontinuance†=70										
102107	Treatment Cycle 2	26	Hypothyroidism	Continuing		2	N	Y	None	Not Resolved
Trial Number=3475-002, Site Number=0090, Subject ID=100630, Gender=F, Race=White, Age=50 Years, Rel Day of Study Medication Discontinuance†=169										
100630	Treatment Cycle 4	64	Hypothyroidism	3.42 Months		1	N	N	None	Resolved
Trial Number=3475-002, Site Number=0151, Subject ID=100088, Gender=M, Race=White, Age=55 Years, Rel Day of Study Medication Discontinuance†=										
100088	Treatment Cycle 10	192	Hypothyroidism	3 Weeks		1	N	Y	None	Resolved
MK-3475 10 mg/kg Q3W										
Trial Number=3475-001, Site Number=0001, Subject ID=001436, Gender=M, Race=White, Age=65 Years, Rel Day of Study Medication Discontinuance†=										
001436	Treatment Cycle 5	106	Hypothyroidism	Continuing	Moderate	2		Y	Interrupted	Not Resolved
Trial Number=3475-001, Site Number=0003, Subject ID=001258, Gender=M, Race=White, Age=42 Years, Rel Day of Study Medication Discontinuance†=65										
001258	Treatment Cycle 4	65	Hypothyroidism	Continuing	Mild	1		N		Not Resolved
Trial Number=3475-001, Site Number=0010, Subject ID=000452, Gender=F, Race=White, Age=33 Years, Rel Day of Study Medication Discontinuance†=233										
000452	Safety Follow-up	240	Hypothyroidism	Continuing	Moderate	2		Y		Not Resolved

C Confidential

付録 2.7.4-70 AEOSI-甲状腺機能低下症を発現した患者の一覧

001 試験+002 試験+006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W										
Trial Number=3475-001, Site Number=0010, Subject ID=000499, Gender=F, Race=White, Age=60 Years, Rel Day of Study Medication Discontinuance†=190										
000499	Treatment Cycle 2	22	Hypothyroidism	Continuing	Moderate	2		Y		Not Resolved
Trial Number=3475-001, Site Number=0010, Subject ID=001220, Gender=M, Race=White, Age=73 Years, Rel Day of Study Medication Discontinuance†=										
001220	Treatment Cycle 12	231	Hypothyroidism	3.22 Months	Moderate	2		Y		Resolved
	Treatment Cycle 16	329	Hypothyroidism	Continuing	Mild	1		Y	N/A	Not Resolved
Trial Number=3475-001, Site Number=0015, Subject ID=000383, Gender=F, Race=White, Age=70 Years, Rel Day of Study Medication Discontinuance†=										
000383	Treatment Cycle 6	106	Hypothyroidism	Continuing	Moderate	2		Y		Not Resolved
Trial Number=3475-001, Site Number=0015, Subject ID=000519, Gender=M, Race=White, Age=70 Years, Rel Day of Study Medication Discontinuance†=										
000519	Treatment Cycle 9	187	Hypothyroidism	Continuing	Moderate	2		Y		Not Resolved
Trial Number=3475-001, Site Number=0019, Subject ID=000367, Gender=F, Race=White, Age=63 Years, Rel Day of Study Medication Discontinuance†=168										
000367	Treatment Cycle 1	5	Hypothyroidism	Continuing	Moderate	2		N		Not Resolved
Trial Number=3475-001, Site Number=0020, Subject ID=000400, Gender=F, Race=White, Age=57 Years, Rel Day of Study Medication Discontinuance†=										
000400	Treatment Cycle 3	57	Hypothyroidism	Continuing	Moderate	2		Y		Not Resolved
Trial Number=3475-001, Site Number=0020, Subject ID=001350, Gender=M, Race=White, Age=44 Years, Rel Day of Study Medication Discontinuance†=85										
001350	Treatment Cycle 5	85	Hypothyroidism	Continuing	Moderate	2		Y		Not Resolved

C Confidential

付録 2.7.4-70 AEOSI-甲状腺機能低下症を発現した患者の一覧

001 試験+002 試験+006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W										
Trial Number=3475-001, Site Number=0020, Subject ID=001353, Gender=F, Race=White, Age=81 Years, Rel Day of Study Medication Discontinuance†=85										
001353	Treatment Cycle 3	42	Hypothyroidism	Continuing	Mild	1		Y	N/A	Not Resolved
Trial Number=3475-001, Site Number=0021, Subject ID=000132, Gender=F, Race=White, Age=38 Years, Rel Day of Study Medication Discontinuance†=153										
000132	Safety Follow-up	171	Hypothyroidism	Continuing	Moderate	2		Y		Not Resolved
Trial Number=3475-001, Site Number=0021, Subject ID=000484, Gender=F, Race=White, Age=67 Years, Rel Day of Study Medication Discontinuance†=106										
000484	Treatment Cycle 3	44	Hypothyroidism	Continuing	Moderate	2		Y		Not Resolved
Trial Number=3475-001, Site Number=0021, Subject ID=001408, Gender=M, Race=White, Age=38 Years, Rel Day of Study Medication Discontinuance†=										
001408	Treatment Cycle 7	127	Hypothyroidism	Continuing	Moderate	2		Y		Not Resolved
Trial Number=3475-001, Site Number=0021, Subject ID=001412, Gender=M, Race=White, Age=57 Years, Rel Day of Study Medication Discontinuance†=										
001412	Treatment Cycle 4	85	Hypothyroidism	Continuing	Moderate	2		Y		Not Resolved
Trial Number=3475-001, Site Number=0021, Subject ID=001448, Gender=F, Race=White, Age=50 Years, Rel Day of Study Medication Discontinuance†=										
001448	Treatment Cycle 6	106	Hypothyroidism	Continuing	Moderate	2		Y		Not Resolved
Trial Number=3475-001, Site Number=0024, Subject ID=000121, Gender=M, Race=White, Age=51 Years, Rel Day of Study Medication Discontinuance†=56										
000121	Treatment Cycle 2	41	Hypothyroidism	1.44 Years	Moderate	2		Y	Interrupted	Resolved
Trial Number=3475-002, Site Number=0016, Subject ID=100627, Gender=M, Race=White, Age=56 Years, Rel Day of Study Medication Discontinuance†=127										

C Confidential

付録 2.7.4-70 AEOSI-甲状腺機能低下症を発現した患者の一覧

001 試験+002 試験+006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W										
Trial Number=3475-002, Site Number=0016, Subject ID=100627, Gender=M, Race=White, Age=56 Years, Rel Day of Study Medication Discontinuance†=127										
100627	Treatment Cycle 2	22	Hypothyroidism	Continuing		2	N	Y	None	Not Resolved
Trial Number=3475-002, Site Number=0021, Subject ID=101218, Gender=F, Race=White, Age=56 Years, Rel Day of Study Medication Discontinuance†=106										
101218	Treatment Cycle 5	105	Hypothyroidism	Continuing		2	N	Y	None	Not Resolved
Trial Number=3475-002, Site Number=0028, Subject ID=102124, Gender=M, Race=White, Age=59 Years, Rel Day of Study Medication Discontinuance†=162										
102124	Treatment Cycle 5	105	Hypothyroidism	Continuing		2	N	Y	None	Not Resolved
Trial Number=3475-002, Site Number=0033, Subject ID=101504, Gender=F, Race=White, Age=43 Years, Rel Day of Study Medication Discontinuance†=112										
101504	Treatment Cycle 4	64	Hypothyroidism	Continuing		1	N	N	N/A	Not Resolved
Trial Number=3475-002, Site Number=0061, Subject ID=100091, Gender=M, Race=White, Age=78 Years, Rel Day of Study Medication Discontinuance†=190										
100091	Treatment Cycle 7	127	Hypothyroidism	Continuing		2	N	Y	None	Not Resolved
Trial Number=3475-002, Site Number=0080, Subject ID=100022, Gender=M, Race=White, Age=45 Years, Rel Day of Study Medication Discontinuance†=										
100022	Treatment Cycle 6	126	Hypothyroidism	2.04 Months		2	N	Y	None	Resolved
Trial Number=3475-002, Site Number=0080, Subject ID=100313, Gender=F, Race=White, Age=68 Years, Rel Day of Study Medication Discontinuance†=										
100313	Treatment Cycle 10	213	Hypothyroidism	1.41 Months		2	N	Y	None	Resolved
Trial Number=3475-002, Site Number=0080, Subject ID=100652, Gender=F, Race=White, Age=62 Years, Rel Day of Study Medication Discontinuance†=										

C Confidential

付録 2.7.4-70 AEOSI-甲状腺機能低下症を発現した患者の一覧

001 試験+002 試験+006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W										
Trial Number=3475-002, Site Number=0080, Subject ID=100652, Gender=F, Race=White, Age=62 Years, Rel Day of Study Medication Discontinuance†=										
100652	Treatment Cycle 3	63	Hypothyroidism	Continuing		2	N	Y	None	Not Resolved
Trial Number=3475-002, Site Number=0088, Subject ID=102142, Gender=M, Race=White, Age=53 Years, Rel Day of Study Medication Discontinuance†=43										
102142	Treatment Cycle 1	8	Hypothyroidism	6 Days		2	N	Y	None	Resolved
		14	Hypothyroidism	Continuing		2	N	Y	None	Not Resolved
Trial Number=3475-002, Site Number=0090, Subject ID=100045, Gender=M, Race=White, Age=62 Years, Rel Day of Study Medication Discontinuance†=										
100045	Treatment Cycle 10	204	Hypothyroidism	Continuing		1	N	Y	None	Not Resolved
Trial Number=3475-002, Site Number=0101, Subject ID=101833, Gender=F, Race=White, Age=80 Years, Rel Day of Study Medication Discontinuance†=65										
101833	Safety Follow-up	85	Hypothyroidism	Continuing		1	N	Y	None	Not Resolved
Trial Number=3475-002, Site Number=0111, Subject ID=100329, Gender=F, Race=White, Age=66 Years, Rel Day of Study Medication Discontinuance†=										
100329	Treatment Cycle 5	105	Hypothyroidism	Continuing		2	N	Y	None	Not Resolved
Trial Number=3475-002, Site Number=0151, Subject ID=100002, Gender=F, Race=White, Age=70 Years, Rel Day of Study Medication Discontinuance†=212										
100002	Treatment Cycle 2	63	Hypothyroidism	Continuing		2	N	Y	None	Not Resolved
Trial Number=3475-002, Site Number=0151, Subject ID=100312, Gender=F, Race=White, Age=54 Years, Rel Day of Study Medication Discontinuance†=										
100312	Treatment Cycle 5	86	Hypothyroidism	Continuing		2	N	N	None	Not Resolved

C Confidential

付録 2.7.4-70 AEOSI-甲状腺機能低下症を発現した患者の一覧

001 試験+002 試験+006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W										
Trial Number=3475-002, Site Number=0170, Subject ID=100622, Gender=M, Race=White, Age=76 Years, Rel Day of Study Medication Discontinuance†=1										
100622	Safety Follow-up	29	Hypothyroidism	Continuing		2	N	Y	None	Not Resolved
Trial Number=3475-006, Site Number=0001, Subject ID=361997, Gender=M, Race=White, Age=60 Years, Rel Day of Study Medication Discontinuance†=211										
361997	Treatment Cycle 9	189	Hypothyroidism	1.41 Months		1	N	Y	None	Resolved
Trial Number=3475-006, Site Number=0300, Subject ID=361650, Gender=M, Race=White, Age=74 Years, Rel Day of Study Medication Discontinuance†=										
361650	Treatment Cycle 4	70	Hypothyroidism	Continuing		1	N	Y	None	Not Resolved
Trial Number=3475-006, Site Number=0312, Subject ID=364060, Gender=M, Race=White, Age=70 Years, Rel Day of Study Medication Discontinuance†=										
364060	Treatment Cycle 3	42	Hypothyroidism	Unknown		2	N	Y	None	Unknown
Trial Number=3475-006, Site Number=0507, Subject ID=366988, Gender=M, Race=Multiple, Age=34 Years, Rel Day of Study Medication Discontinuance†=										
366988	Treatment Cycle 7	147	Hypothyroidism	Continuing		1	N	Y	None	Not Resolved
Trial Number=3475-006, Site Number=0605, Subject ID=360489, Gender=F, Race=White, Age=61 Years, Rel Day of Study Medication Discontinuance†=54										
360489	Treatment Cycle 3	54	Hypothyroidism	Continuing		2	N	Y	None	Not Resolved
Trial Number=3475-006, Site Number=0605, Subject ID=362662, Gender=F, Race=White, Age=38 Years, Rel Day of Study Medication Discontinuance†=232										
362662	Treatment Cycle 2	20	Hypothyroidism	9.72 Months		2	N	Y	None	Resolved
Trial Number=3475-006, Site Number=0605, Subject ID=367085, Gender=M, Race=White, Age=64 Years, Rel Day of Study Medication Discontinuance†=147										

C Confidential

付録 2.7.4-70 AEOSI-甲状腺機能低下症を発現した患者の一覧

001 試験+002 試験+006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W										
Trial Number=3475-006, Site Number=0605, Subject ID=367085, Gender=M, Race=White, Age=64 Years, Rel Day of Study Medication Discontinuance†=147										
367085	Treatment Cycle 6	105	Hypothyroidism	3.14 Weeks		1	N	Y	None	Resolved
Trial Number=3475-006, Site Number=0607, Subject ID=364455, Gender=M, Race=White, Age=77 Years, Rel Day of Study Medication Discontinuance†=										
364455	Treatment Cycle 10	197	Hypothyroidism	Continuing		2	N	Y	None	Not Resolved
Trial Number=3475-006, Site Number=0611, Subject ID=361610, Gender=F, Race=White, Age=40 Years, Rel Day of Study Medication Discontinuance†=127										
361610	Treatment Cycle 3	43	Hypothyroidism	Continuing		1	N	Y	None	Not Resolved
Trial Number=3475-006, Site Number=0612, Subject ID=361134, Gender=F, Race=White, Age=53 Years, Rel Day of Study Medication Discontinuance†=										
361134	Treatment Cycle 5	94	Hypothyroidism	1.45 Months		1	N	Y	None	Resolved
Trial Number=3475-006, Site Number=0612, Subject ID=363119, Gender=F, Race=White, Age=59 Years, Rel Day of Study Medication Discontinuance†=173										
363119	Treatment Cycle 7	131	Hypothyroidism	1.41 Months		1	N	Y	None	Resolved
Trial Number=3475-006, Site Number=0702, Subject ID=367414, Gender=F, Race=White, Age=62 Years, Rel Day of Study Medication Discontinuance†=										
367414	Treatment Cycle 6	107	Hypothyroidism	Continuing		2	N	Y	None	Not Resolved
Trial Number=3475-006, Site Number=0901, Subject ID=365724, Gender=F, Race=White, Age=63 Years, Rel Day of Study Medication Discontinuance†=										
365724	Treatment Cycle 6	106	Hypothyroidism	Continuing		2	N	Y	None	Not Resolved
Trial Number=3475-006, Site Number=1500, Subject ID=363996, Gender=M, Race=White, Age=42 Years, Rel Day of Study Medication Discontinuance†=22										

C Confidential

付録 2.7.4-70 AEOSI-甲状腺機能低下症を発現した患者の一覧

001 試験+002 試験+006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W										
Trial Number=3475-006, Site Number=1500, Subject ID=363996, Gender=M, Race=White, Age=42 Years, Rel Day of Study Medication Discontinuance†=22										
363996	Safety Follow-up	43	Hypothyroidism	Continuing		2	N	Y	None	Not Resolved
Trial Number=3475-006, Site Number=1502, Subject ID=369150, Gender=F, Race=White, Age=84 Years, Rel Day of Study Medication Discontinuance†=107										
369150	Treatment Cycle 4	65	Primary hypothyroidism	Continuing		2	N	Y	None	Not Resolved
Trial Number=3475-006, Site Number=1504, Subject ID=365695, Gender=M, Race=White, Age=65 Years, Rel Day of Study Medication Discontinuance†=										
365695	Treatment Cycle 7	143	Hypothyroidism	Continuing		2	N	Y	None	Resolving
Trial Number=3475-006, Site Number=1603, Subject ID=360612, Gender=M, Race=White, Age=65 Years, Rel Day of Study Medication Discontinuance†=										
360612	Treatment Cycle 7	127	Hypothyroidism	Continuing		2	N	Y	None	Not Resolved
Trial Number=3475-006, Site Number=1703, Subject ID=363479, Gender=M, Race=White, Age=64 Years, Rel Day of Study Medication Discontinuance†=										
363479	Treatment Cycle 7	148	Hypothyroidism	4.93 Months		2	N	Y	Interrupted	Resolved
Trial Number=3475-006, Site Number=1707, Subject ID=362376, Gender=F, Race=White, Age=68 Years, Rel Day of Study Medication Discontinuance†=										
362376	Treatment Cycle 4	83	Hypothyroidism	1.68 Months		2	N	Y	Interrupted	Resolved
Trial Number=3475-006, Site Number=1711, Subject ID=366346, Gender=F, Race=White, Age=55 Years, Rel Day of Study Medication Discontinuance†=65										
366346	Treatment Cycle 1	11	Hypothyroidism	Continuing		2	N	N	None	Not Resolved
Trial Number=3475-006, Site Number=1804, Subject ID=363862, Gender=M, Race=White, Age=71 Years, Rel Day of Study Medication Discontinuance†=41										

C Confidential

付録 2.7.4-70 AEOSI-甲状腺機能低下症を発現した患者の一覧

001 試験+002 試験+006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W										
Trial Number=3475-006, Site Number=1804, Subject ID=363862, Gender=M, Race=White, Age=71 Years, Rel Day of Study Medication Discontinuance†=41										
363862	Treatment Cycle 2	18	Hypothyroidism	3.43 Weeks		1	N	N	None	Resolved
Trial Number=3475-006, Site Number=1810, Subject ID=369578, Gender=F, Race=White, Age=62 Years, Rel Day of Study Medication Discontinuance†=										
369578	Treatment Cycle 4	64	Hypothyroidism	Continuing		2	N	Y	None	Not Resolved
Trial Number=3475-006, Site Number=1818, Subject ID=364877, Gender=M, Race=White, Age=80 Years, Rel Day of Study Medication Discontinuance†=										
364877	Treatment Cycle 8	148	Hypothyroidism	Continuing		2	N	Y	None	Not Resolved
Trial Number=3475-006, Site Number=1820, Subject ID=367788, Gender=M, Race=White, Age=33 Years, Rel Day of Study Medication Discontinuance†=										
367788	Treatment Cycle 6	107	Hypothyroidism	Continuing		1	N	Y	None	Not Resolved
MK-3475 10 mg/kg Q2W										
Trial Number=3475-001, Site Number=0001, Subject ID=001209, Gender=M, Race=White, Age=69 Years, Rel Day of Study Medication Discontinuance†=										
001209	Treatment Cycle 13	184	Hypothyroidism	Continuing	Moderate	2		Y		Not Resolved
Trial Number=3475-001, Site Number=0002, Subject ID=000057, Gender=F, Race=White, Age=72 Years, Rel Day of Study Medication Discontinuance†=										
000057	Treatment Cycle 6	143	Hypothyroidism	3.42 Months	Mild	1		Y	N/A	Resolved
	Treatment Cycle 11	247	Hypothyroidism	1.78 Years	Moderate	2		Y		Resolved
Trial Number=3475-001, Site Number=0002, Subject ID=001294, Gender=M, Race=White, Age=52 Years, Rel Day of Study Medication Discontinuance†=										

C Confidential

付録 2.7.4-70 AEOSI-甲状腺機能低下症を発現した患者の一覧

001 試験+002 試験+006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q2W										
Trial Number=3475-001, Site Number=0002, Subject ID=001294, Gender=M, Race=White, Age=52 Years, Rel Day of Study Medication Discontinuance†=										
001294	Treatment Cycle 15	195	Hypothyroidism	1.41 Months	Mild	1		Y	N/A	Resolved
	Treatment Cycle 18	238	Hypothyroidism	2.3 Months	Moderate	2		Y		Resolved
Trial Number=3475-001, Site Number=0003, Subject ID=000067, Gender=F, Race=White, Age=51 Years, Rel Day of Study Medication Discontinuance†=										
000067	Treatment Cycle 8	106	Hypothyroidism	Continuing	Moderate	2		Y		Not Resolved
Trial Number=3475-001, Site Number=0003, Subject ID=000098, Gender=M, Race=White, Age=59 Years, Rel Day of Study Medication Discontinuance†=										
000098	Treatment Cycle 6	81	Hypothyroidism	1.02 Months	Severe	3		Y	Interrupted	Resolved
	Treatment Cycle 8	134	Hypothyroidism	Continuing	Moderate	2		Y		Not Resolved
Trial Number=3475-001, Site Number=0010, Subject ID=000030, Gender=F, Race=White, Age=81 Years, Rel Day of Study Medication Discontinuance†=309										
000030	Treatment Cycle 10	141	Hypothyroidism	Continuing	Moderate	2		Y	Interrupted	Not Resolved
Trial Number=3475-001, Site Number=0010, Subject ID=000031, Gender=M, Race=White, Age=77 Years, Rel Day of Study Medication Discontinuance†=										
000031	Treatment Cycle 10	126	Hypothyroidism	Continuing	Moderate	2		Y		Not Resolved
Trial Number=3475-001, Site Number=0010, Subject ID=000033, Gender=F, Race=White, Age=61 Years, Rel Day of Study Medication Discontinuance†=										
000033	Treatment Cycle 10	141	Hypothyroidism	Continuing	Moderate	2		N		Not Resolved
Trial Number=3475-001, Site Number=0010, Subject ID=000045, Gender=M, Race=White, Age=70 Years, Rel Day of Study Medication Discontinuance†=441										
000045	Treatment Cycle 8	99	Hypothyroidism	Continuing	Moderate	2		Y	Interrupted	Not Resolved

C Confidential

付録 2.7.4-70 AEOSI-甲状腺機能低下症を発現した患者の一覧

001 試験+002 試験+006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q2W										
Trial Number=3475-001, Site Number=0010, Subject ID=001211, Gender=M, Race=White, Age=65 Years, Rel Day of Study Medication Discontinuance†=										
001211	Treatment Cycle 5	84	Hypothyroidism	4.14 Weeks	Mild	1		Y		Resolved
	Treatment Cycle 7	113	Hypothyroidism	Continuing	Moderate	2		Y		Not Resolved
Trial Number=3475-001, Site Number=0010, Subject ID=001221, Gender=M, Race=White, Age=51 Years, Rel Day of Study Medication Discontinuance†=										
001221	Treatment Cycle 8	99	Hypothyroidism	Continuing	Mild	1		Y		Not Resolved
Trial Number=3475-001, Site Number=0015, Subject ID=000038, Gender=F, Race=White, Age=89 Years, Rel Day of Study Medication Discontinuance†=313										
000038	Treatment Cycle 10	130	Hypothyroidism	Continuing	Moderate	2		Y		Not Resolved
Trial Number=3475-001, Site Number=0015, Subject ID=001285, Gender=M, Race=White, Age=38 Years, Rel Day of Study Medication Discontinuance†=										
001285	Treatment Cycle 9	113	Hypothyroidism	Continuing	Moderate	2		Y		Not Resolved
Trial Number=3475-001, Site Number=0019, Subject ID=000040, Gender=F, Race=White, Age=44 Years, Rel Day of Study Medication Discontinuance†=										
000040	Treatment Cycle 17	230	Hypothyroidism	Continuing	Moderate	2		Y		Not Resolved
Trial Number=3475-001, Site Number=0019, Subject ID=001291, Gender=F, Race=White, Age=67 Years, Rel Day of Study Medication Discontinuance†=										
001291	Treatment Cycle 8	106	Hypothyroidism	Continuing	Moderate	2		Y		Not Resolved
Trial Number=3475-001, Site Number=0020, Subject ID=001390, Gender=F, Race=White, Age=48 Years, Rel Day of Study Medication Discontinuance†=85										
001390	Safety Follow-up	111	Hypothyroidism	Continuing	Moderate	2		Y		Not Resolved

C Confidential

付録 2.7.4-70 AEOSI-甲状腺機能低下症を発現した患者の一覧

001 試験+002 試験+006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q2W										
Trial Number=3475-001, Site Number=0020, Subject ID=001404, Gender=F, Race=White, Age=42 Years, Rel Day of Study Medication Discontinuance†=71										
001404	Treatment Cycle 4	56	Hypothyroidism	Continuing	Moderate	2		Y		Not Resolved
Trial Number=3475-001, Site Number=0021, Subject ID=000078, Gender=F, Race=White, Age=38 Years, Rel Day of Study Medication Discontinuance†=										
000078	Treatment Cycle 38	576	Hypothyroidism	Continuing	Moderate	2		Y		Not Resolved
Trial Number=3475-006, Site Number=0001, Subject ID=368185, Gender=F, Race=White, Age=42 Years, Rel Day of Study Medication Discontinuance†=279										
368185	Treatment Cycle 3	40	Hypothyroidism	1.64 Months		1	N	Y	None	Resolved
Trial Number=3475-006, Site Number=0002, Subject ID=360490, Gender=F, Race=White, Age=57 Years, Rel Day of Study Medication Discontinuance†=99										
360490	Safety Follow-up	113	Hypothyroidism	Continuing		2	N	Y	N/A	Not Resolved
Trial Number=3475-006, Site Number=0003, Subject ID=362014, Gender=M, Race=White, Age=78 Years, Rel Day of Study Medication Discontinuance†=										
362014	Treatment Cycle 6	84	Hypothyroidism	Continuing		2	N	Y	None	Not Resolved
Trial Number=3475-006, Site Number=0005, Subject ID=362871, Gender=M, Race=White, Age=36 Years, Rel Day of Study Medication Discontinuance†=279										
362871	Treatment Cycle 12	153	Hypothyroidism	Continuing		2	N	Y	None	Not Resolved
Trial Number=3475-006, Site Number=0102, Subject ID=365853, Gender=F, Race=White, Age=66 Years, Rel Day of Study Medication Discontinuance†=										
365853	Treatment Cycle 11	143	Hypothyroidism	Continuing		1	N	N	None	Not Resolved
Trial Number=3475-006, Site Number=0300, Subject ID=369262, Gender=M, Race=White, Age=54 Years, Rel Day of Study Medication Discontinuance†=										

C Confidential

付録 2.7.4-70 AEOSI-甲状腺機能低下症を発現した患者の一覧

001 試験+002 試験+006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q2W										
Trial Number=3475-006, Site Number=0300, Subject ID=369262, Gender=M, Race=White, Age=54 Years, Rel Day of Study Medication Discontinuance†=										
369262	Treatment Cycle 8	106	Hypothyroidism	Continuing		2	N	Y	None	Not Resolved
Trial Number=3475-006, Site Number=0400, Subject ID=369352, Gender=F, Race=White, Age=26 Years, Rel Day of Study Medication Discontinuance†=99										
369352	Treatment Cycle 6	71	Hypothyroidism	Continuing		2	N	Y	None	Not Resolved
Trial Number=3475-006, Site Number=0600, Subject ID=368594, Gender=F, Race=White, Age=72 Years, Rel Day of Study Medication Discontinuance†=										
368594	Treatment Cycle 14	186	Hypothyroidism	2.56 Months		2	N	Y	None	Resolved
Trial Number=3475-006, Site Number=0601, Subject ID=366173, Gender=F, Race=White, Age=63 Years, Rel Day of Study Medication Discontinuance†=										
366173	Treatment Cycle 2	39	Hypothyroidism	Continuing		2	N	Y	None	Not Resolved
Trial Number=3475-006, Site Number=0605, Subject ID=366008, Gender=F, Race=White, Age=74 Years, Rel Day of Study Medication Discontinuance†=100										
366008	Treatment Cycle 8	100	Hypothyroidism	Continuing		2	N	Y	None	Not Resolved
Trial Number=3475-006, Site Number=0605, Subject ID=366351, Gender=F, Race=White, Age=46 Years, Rel Day of Study Medication Discontinuance†=										
366351	Treatment Cycle 5	58	Hypothyroidism	Continuing		2	N	Y	None	Not Resolved
Trial Number=3475-006, Site Number=0700, Subject ID=363097, Gender=F, Race=White, Age=71 Years, Rel Day of Study Medication Discontinuance†=										
363097	Treatment Cycle 5	70	Hypothyroidism	3.25 Months		2	N	Y	None	Resolved
Trial Number=3475-006, Site Number=0704, Subject ID=360742, Gender=F, Race=White, Age=83 Years, Rel Day of Study Medication Discontinuance†=154										

C Confidential

付録 2.7.4-70 AEOSI-甲状腺機能低下症を発現した患者の一覧

001 試験+002 試験+006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q2W										
Trial Number=3475-006, Site Number=0704, Subject ID=360742, Gender=F, Race=White, Age=83 Years, Rel Day of Study Medication Discontinuance†=154										
360742	Treatment Cycle 4	42	Hypothyroidism	Continuing		2	N	Y	Interrupted	Not Resolved
Trial Number=3475-006, Site Number=0706, Subject ID=369101, Gender=M, Race=White, Age=44 Years, Rel Day of Study Medication Discontinuance†=										
369101	Treatment Cycle 9	140	Hypothyroidism	2.14 Weeks		1	N	N	None	Resolved
Trial Number=3475-006, Site Number=0900, Subject ID=361895, Gender=F, Race=White, Age=37 Years, Rel Day of Study Medication Discontinuance†=										
361895	Treatment Cycle 11	142	Hypothyroidism	3.86 Weeks		1	N	Y	None	Resolved
Trial Number=3475-006, Site Number=0902, Subject ID=364274, Gender=M, Race=White, Age=34 Years, Rel Day of Study Medication Discontinuance†=										
364274	Treatment Cycle 16	211	Hypothyroidism	Continuing		1	N	Y	None	Not Resolved
Trial Number=3475-006, Site Number=0902, Subject ID=369337, Gender=M, Race=White, Age=56 Years, Rel Day of Study Medication Discontinuance†=										
369337	Treatment Cycle 7	96	Hypothyroidism	Continuing		2	N	Y	None	Not Resolved
Trial Number=3475-006, Site Number=1301, Subject ID=368724, Gender=M, Race=White, Age=73 Years, Rel Day of Study Medication Discontinuance†=204										
368724	Treatment Cycle 6	71	Hypothyroidism	Continuing		2	N	Y	None	Resolving
Trial Number=3475-006, Site Number=1502, Subject ID=361305, Gender=F, Race=White, Age=62 Years, Rel Day of Study Medication Discontinuance†=100										
361305	Safety Follow-up	114	Hypothyroidism	Continuing		1	N	Y	None	Not Resolved
Trial Number=3475-006, Site Number=1504, Subject ID=366969, Gender=M, Race=White, Age=71 Years, Rel Day of Study Medication Discontinuance†=										

C Confidential

付録 2.7.4-70 AEOSI-甲状腺機能低下症を発現した患者の一覧

001 試験+002 試験+006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q2W										
Trial Number=3475-006, Site Number=1504, Subject ID=366969, Gender=M, Race=White, Age=71 Years, Rel Day of Study Medication Discontinuance†=										
366969	Treatment Cycle 16	224	Hypothyroidism	2.14 Weeks		1	N	N	None	Resolved
Trial Number=3475-006, Site Number=1600, Subject ID=361918, Gender=F, Race=White, Age=58 Years, Rel Day of Study Medication Discontinuance†=										
361918	Treatment Cycle 7	96	Hypothyroidism	Continuing		2	N	Y	None	Not Resolved
Trial Number=3475-006, Site Number=1708, Subject ID=363322, Gender=M, Race=White, Age=52 Years, Rel Day of Study Medication Discontinuance†=281										
363322	Treatment Cycle 6	70	Hypothyroidism	1.87 Months		1	N	Y	None	Resolved
Trial Number=3475-006, Site Number=1808, Subject ID=366961, Gender=F, Race=White, Age=79 Years, Rel Day of Study Medication Discontinuance†=141										
366961	Treatment Cycle 6	72	Hypothyroidism	Continuing		1	N	Y	None	Not Resolved
Trial Number=3475-006, Site Number=1818, Subject ID=367651, Gender=M, Race=White, Age=75 Years, Rel Day of Study Medication Discontinuance†=309										
367651	Treatment Cycle 8	99	Hypothyroidism	Continuing		2	N	Y	None	Not Resolved
Trial Number=3475-006, Site Number=1819, Subject ID=365965, Gender=M, Race=White, Age=40 Years, Rel Day of Study Medication Discontinuance†=										
365965	Treatment Cycle 10	127	Hypothyroidism	Continuing		3	N	Y	None	Not Resolved
Trial Number=3475-006, Site Number=1819, Subject ID=367668, Gender=M, Race=White, Age=47 Years, Rel Day of Study Medication Discontinuance†=85										
367668	Treatment Cycle 4	43	Hypothyroidism	Continuing		2	N	Y	None	Not Resolved
Trial Number=3475-006, Site Number=1823, Subject ID=360915, Gender=M, Race=White, Age=60 Years, Rel Day of Study Medication Discontinuance†=146										

C Confidential

付録 2.7.4-70 AEOSI-甲状腺機能低下症を発現した患者の一覧

001 試験+002 試験+006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q2W										
Trial Number=3475-006, Site Number=1823, Subject ID=360915, Gender=M, Race=White, Age=60 Years, Rel Day of Study Medication Discontinuance†=146										
360915	Treatment Cycle 6	69	Hypothyroidism	Continuing		2	N	Y	None	Not Resolved
Trial Number=3475-006, Site Number=1901, Subject ID=365696, Gender=M, Race=White, Age=65 Years, Rel Day of Study Medication Discontinuance†=71										
365696	Treatment Cycle 4	43	Hypothyroidism	Continuing		1	N	Y	None	Not Resolved

†Relative Day of Study Medication Discontinuance is defined as the day of the last recorded dose of study medication for the subject relative to the start of study medication.

Action Taken: None = DOSE NOT CHANGED, Reduced = DOSE REDUCED, Interrupted = DRUG INTERRUPTED, Discontinued = DRUG WITHDRAWN, Increased = DOSE INCREASED, N/A = NOT APPLICABLE.

Outcome: Resolved = RECOVERED/RESOLVED, Resolving = RECOVERING/RESOLVING, Sequelae = RECOVERED/RESOLVED WITH SEQUELAE, Not resolved = NOT RECOVERED/NOT RESOLVED.

Related: Investigator-assessed relationship of the adverse event to study medication.

Grades are based on NCI CTCAE version 4.0.

(MK-3475 PN001 Database Cutoff Date: [redacted].

(MK-3475 PN002 Database Cutoff Date: 12MAY2014).

(MK-3475 PN006 Database Cutoff Date: 03SEP2014).

C Confidential

付録 2.7.4-71 AEOSI-甲状腺機能低下症に対する副腎皮質ホルモン剤使用の一覧
001 試験+002 試験+006 試験（APaT 集団）

Subject ID	Med. Start Day	Med. Duration (Days)	Med. Name	Total Daily Dose	Frequency	Route	Prednisone Equiv.† (mg)	Adverse Event for Use	AE Start Day	AE End Day	AE Toxicity Grade
MK-3475 10 mg/kg Q3W											
Trial Number=3475-001, Site Number=0021, Subject ID=000484, Gender=F, Race=White, Age=67 Years, Rel Day of Study Medication Discontinuance‡=106											
000484	86	.	Hydrocortisone	30	QD	Oral Administration	7.50	Hypothyroidism	44	.	2
	75	4	Prednisone	60	QD	Oral Administration	60.00	Hypothyroidism	44	.	2
Trial Number=3475-002, Site Number=0080, Subject ID=100022, Gender=M, Race=White, Age=45 Years, Rel Day of Study Medication Discontinuance‡=											
100022	156	94	Hydrocortisone	30	QD	Oral	7.50	Hypothyroidism	126	187	2
	156	94	Hydrocortisone	30	QD	Oral	7.50	Hypothyroidism	126	187	2

付録 2.7.4-71 AEOSI-甲状腺機能低下症に対する副腎皮質ホルモン剤使用の一覧
001 試験+002 試験+006 試験（APaT 集団）（続き）

Subject ID	Med. Start Day	Med. Duration (Days)	Med. Name	Total Daily Dose	Frequency	Route	Prednisone Equiv.† (mg)	Adverse Event for Use	AE Start Day	AE End Day	AE Toxicity Grade
MK-3475 10 mg/kg Q2W											
Trial Number=3475-006, Site Number=0700, Subject ID=363097, Gender=F, Race=White, Age=71 Years, Rel Day of Study Medication Discontinuance‡=											
363097	71	1	Hydrocortisone	100	ONCE	Intravenous	25.00	Hypothyroidism	70	168	2

Med.: Medication.
Equiv.: Equivalent.
AE: Adverse Event.
†: Prednisone equivalent total daily dose.
‡Relative Day of Study Medication Discontinuance is defined as the day of the last recorded dose of study medication for the subject relative to the start of study medication.
AE start date is defined as the start day of the adverse event for the subject relative to the start of study medication.
Grades are based on NCI CTCAE version 4.0.
(MK-3475 PN001 Database Cutoff Date: [redacted].
(MK-3475 PN002 Database Cutoff Date: 12MAY2014).
(MK-3475 PN006 Database Cutoff Date: 03SEP2014).

C Confidential

付録 2.7.4-72 AEOSI-甲状腺機能亢進症を発現した患者の一覧

001 試験+002 試験+006 試験（APaT 集団）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 2 mg/kg Q3W										
Trial Number=3475-001, Site Number=0012, Subject ID=000389, Gender=F, Race=White, Age=68 Years, Rel Day of Study Medication Discontinuance†=22										
000389	Safety Follow-up	40	Hyperthyroidism	6.08 Months	Moderate	2	Y	Y	Discontinued	Resolved
Trial Number=3475-001, Site Number=0021, Subject ID=000542, Gender=M, Race=White, Age=74 Years, Rel Day of Study Medication Discontinuance†=515										
000542	Treatment Cycle 3	43	Hyperthyroidism	2.76 Months	Mild	1		Y	N/A	Resolved
Trial Number=3475-002, Site Number=0010, Subject ID=100334, Gender=F, Race=White, Age=33 Years, Rel Day of Study Medication Discontinuance†=127										
100334	Treatment Cycle 1	22	Hyperthyroidism	2.83 Months		1	N	Y	None	Resolved
Trial Number=3475-002, Site Number=0033, Subject ID=100325, Gender=F, Race=White, Age=49 Years, Rel Day of Study Medication Discontinuance†=										
100325	Treatment Cycle 2	43	Hyperthyroidism	2.1 Months		1	N	Y	None	Resolved
Trial Number=3475-002, Site Number=0088, Subject ID=101506, Gender=M, Race=White, Age=57 Years, Rel Day of Study Medication Discontinuance†=126										
101506	Treatment Cycle 1	1	Hyperthyroidism	3.86 Weeks		1	N	N	None	Resolved
	Treatment Cycle 5	81	Hyperthyroidism	1.43 Weeks		1	N	Y	None	Resolved
	Treatment Cycle 6	104	Hyperthyroidism	1.68 Months		1	N	Y	None	Resolved
Trial Number=3475-002, Site Number=0140, Subject ID=100109, Gender=M, Race=White, Age=33 Years, Rel Day of Study Medication Discontinuance†=232										
100109	Treatment Cycle 6	106	Hyperthyroidism	Continuing		1	N	Y	None	Not Resolved
Trial Number=3475-002, Site Number=0150, Subject ID=101223, Gender=F, Race=White, Age=84 Years, Rel Day of Study Medication Discontinuance†=										
101223	Treatment Cycle 12	253	Hyperthyroidism	Unknown		1	N	Y	None	Unknown

C Confidential

付録 2.7.4-72 AEOSI-甲状腺機能亢進症を発現した患者の一覧

001 試験+002 試験+006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 2 mg/kg Q3W										
Trial Number=3475-002, Site Number=0151, Subject ID=100007, Gender=M, Race=White, Age=65 Years, Rel Day of Study Medication Discontinuance†=										
100007	Treatment Cycle 2	25	Hyperthyroidism	5.91 Months		2	N	Y	None	Resolved
Trial Number=3475-002, Site Number=0151, Subject ID=100088, Gender=M, Race=White, Age=55 Years, Rel Day of Study Medication Discontinuance†=										
100088	Treatment Cycle 5	88	Hyperthyroidism	1.35 Months		1	N	Y	None	Resolved
MK-3475 10 mg/kg Q3W										
Trial Number=3475-001, Site Number=0011, Subject ID=001396, Gender=F, Race=White, Age=71 Years, Rel Day of Study Medication Discontinuance†=										
001396	Treatment Cycle 2	22	Hyperthyroidism	1.38 Months	Mild	1		Y	N/A	Resolved
Trial Number=3475-001, Site Number=0016, Subject ID=000327, Gender=F, Race=White, Age=48 Years, Rel Day of Study Medication Discontinuance†=358										
000327	Treatment Cycle 4	64	Hyperthyroidism	4.11 Months	Mild	1		Y	N/A	Resolved
Trial Number=3475-001, Site Number=0020, Subject ID=000400, Gender=F, Race=White, Age=57 Years, Rel Day of Study Medication Discontinuance†=										
000400	Treatment Cycle 1	15	Hyperthyroidism	1.41 Months	Moderate	2		Y		Resolved
Trial Number=3475-001, Site Number=0020, Subject ID=001350, Gender=M, Race=White, Age=44 Years, Rel Day of Study Medication Discontinuance†=85										
001350	Treatment Cycle 3	43	Hyperthyroidism	1.41 Months	Mild	1		Y	N/A	Resolved
Trial Number=3475-001, Site Number=0021, Subject ID=001405, Gender=M, Race=White, Age=57 Years, Rel Day of Study Medication Discontinuance†=										
001405	Treatment Cycle 5	84	Hyperthyroidism	Continuing	Mild	1		Y	N/A	Not Resolved

C Confidential

付録 2.7.4-72 AEOSI-甲状腺機能亢進症を発現した患者の一覧

001 試験+002 試験+006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W										
Trial Number=3475-001, Site Number=0021, Subject ID=001408, Gender=M, Race=White, Age=38 Years, Rel Day of Study Medication Discontinuance†=										
001408	Treatment Cycle 3	43	Hyperthyroidism	2.76 Months	Mild	1		Y	N/A	Resolved
Trial Number=3475-001, Site Number=0021, Subject ID=001412, Gender=M, Race=White, Age=57 Years, Rel Day of Study Medication Discontinuance†=										
001412	Treatment Cycle 2	37	Hyperthyroidism	4 Weeks	Severe	3	Y	Y	Interrupted	Resolved
Trial Number=3475-002, Site Number=0033, Subject ID=100609, Gender=M, Race=White, Age=43 Years, Rel Day of Study Medication Discontinuance†=										
100609	Treatment Cycle 2	23	Hyperthyroidism	Continuing		1	N	N	N/A	Not Resolved
Trial Number=3475-002, Site Number=0070, Subject ID=100108, Gender=M, Race=White, Age=51 Years, Rel Day of Study Medication Discontinuance†=148										
100108	Treatment Cycle 3	64	Hyperthyroidism	1.41 Months		1	N	Y	None	Resolved
Trial Number=3475-006, Site Number=0003, Subject ID=365319, Gender=M, Race=White, Age=81 Years, Rel Day of Study Medication Discontinuance†=										
365319	Treatment Cycle 3	43	Hyperthyroidism	Continuing		1	N	Y	None	Not Resolved
Trial Number=3475-006, Site Number=0301, Subject ID=364220, Gender=F, Race=White, Age=56 Years, Rel Day of Study Medication Discontinuance†=188										
364220	Treatment Cycle 3	41	Hyperthyroidism	Continuing		1	N	Y	None	Not Resolved
Trial Number=3475-006, Site Number=0601, Subject ID=362914, Gender=M, Race=White, Age=39 Years, Rel Day of Study Medication Discontinuance†=										
362914	Treatment Cycle 11	225	Hyperthyroidism	Continuing		1	N	N	None	Not Resolved
Trial Number=3475-006, Site Number=0605, Subject ID=360080, Gender=M, Race=White, Age=61 Years, Rel Day of Study Medication Discontinuance†=274										

C Confidential

付録 2.7.4-72 AEOSI-甲状腺機能亢進症を発現した患者の一覧

001 試験+002 試験+006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W										
Trial Number=3475-006, Site Number=0605, Subject ID=360080, Gender=M, Race=White, Age=61 Years, Rel Day of Study Medication Discontinuance†=274										
360080	Treatment Cycle 8	148	Hyperthyroidism	3.48 Months		2	N	Y	None	Resolved
Trial Number=3475-006, Site Number=0605, Subject ID=364113, Gender=F, Race=White, Age=52 Years, Rel Day of Study Medication Discontinuance†=										
364113	Treatment Cycle 3	44	Hyperthyroidism	Continuing		1	N	Y	None	Not Resolved
Trial Number=3475-006, Site Number=0612, Subject ID=361134, Gender=F, Race=White, Age=53 Years, Rel Day of Study Medication Discontinuance†=										
361134	Treatment Cycle 1	26	Hyperthyroidism	3.86 Weeks		2	N	Y	Interrupted	Resolved
Trial Number=3475-006, Site Number=0902, Subject ID=362669, Gender=M, Race=White, Age=62 Years, Rel Day of Study Medication Discontinuance†=127										
362669	Treatment Cycle 3	43	Hyperthyroidism	2.04 Months		1	N	Y	None	Resolved
Trial Number=3475-006, Site Number=1820, Subject ID=367788, Gender=M, Race=White, Age=33 Years, Rel Day of Study Medication Discontinuance†=										
367788	Treatment Cycle 3	46	Hyperthyroidism	2.04 Months		2	N	N	None	Resolved
Trial Number=3475-006, Site Number=1900, Subject ID=362368, Gender=F, Race=White, Age=32 Years, Rel Day of Study Medication Discontinuance†=										
362368	Treatment Cycle 7	125	Hyperthyroidism	Unknown		1	N	Y	None	Unknown
MK-3475 10 mg/kg Q2W										
Trial Number=3475-001, Site Number=0010, Subject ID=000031, Gender=M, Race=White, Age=77 Years, Rel Day of Study Medication Discontinuance†=										
000031	Treatment Cycle 46	665	Hyperthyroidism	Continuing	Mild	1		N	N/A	Not Resolved

C Confidential

付録 2.7.4-72 AEOSI-甲状腺機能亢進症を発現した患者の一覧

001 試験+002 試験+006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q2W										
Trial Number=3475-001, Site Number=0010, Subject ID=000031, Gender=M, Race=White, Age=77 Years, Rel Day of Study Medication Discontinuance†=										
000031	Treatment Cycle 59	835	Hyperthyroidism	Continuing	Mild	1		N	N/A	Not Resolved
Trial Number=3475-001, Site Number=0010, Subject ID=001201, Gender=M, Race=Asian, Age=74 Years, Rel Day of Study Medication Discontinuance†=										
001201	Treatment Cycle 16	239	Hyperthyroidism	3.42 Months	Mild	1		Y	N/A	Resolved
	Treatment Cycle 23	343	Hyperthyroidism	2.56 Months	Moderate	2		Y	Interrupted	Resolved
Trial Number=3475-001, Site Number=0013, Subject ID=000084, Gender=F, Race=White, Age=52 Years, Rel Day of Study Medication Discontinuance†=43										
000084	Safety Follow-up	51	Hyperthyroidism	4.14 Weeks	Severe	3	Y	Y	Discontinued	Resolved
Trial Number=3475-001, Site Number=0019, Subject ID=001247, Gender=M, Race=White, Age=61 Years, Rel Day of Study Medication Discontinuance†=337										
001247	Treatment Cycle 1	6	Hyperthyroidism	2.83 Months	Mild	1		N	N/A	Resolved
Trial Number=3475-001, Site Number=0020, Subject ID=001390, Gender=F, Race=White, Age=48 Years, Rel Day of Study Medication Discontinuance†=85										
001390	Treatment Cycle 5	57	Hyperthyroidism	1.77 Months	Mild	1		Y		Resolved
Trial Number=3475-001, Site Number=0020, Subject ID=001404, Gender=F, Race=White, Age=42 Years, Rel Day of Study Medication Discontinuance†=71										
001404	Treatment Cycle 2	15	Hyperthyroidism	4.14 Weeks	Mild	1		Y	N/A	Resolved
Trial Number=3475-006, Site Number=0003, Subject ID=362014, Gender=M, Race=White, Age=78 Years, Rel Day of Study Medication Discontinuance†=										
362014	Treatment Cycle 2	28	Hyperthyroidism	1.84 Months		1	N	Y	None	Resolved

C Confidential

付録 2.7.4-72 AEOSI-甲状腺機能亢進症を発現した患者の一覧

001 試験+002 試験+006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q2W										
Trial Number=3475-006, Site Number=0300, Subject ID=369262, Gender=M, Race=White, Age=54 Years, Rel Day of Study Medication Discontinuance†=										
369262	Treatment Cycle 4	50	Hyperthyroidism	1.84 Months		2	N	Y	None	Resolved
Trial Number=3475-006, Site Number=0312, Subject ID=364603, Gender=M, Race=White, Age=47 Years, Rel Day of Study Medication Discontinuance†=										
364603	Treatment Cycle 14	183	Hyperthyroidism	Continuing		1	N	Y	None	Not Resolved
Trial Number=3475-006, Site Number=0601, Subject ID=366173, Gender=F, Race=White, Age=63 Years, Rel Day of Study Medication Discontinuance†=										
366173	Treatment Cycle 2	24	Hyperthyroidism	2.29 Weeks		1	N	Y	None	Resolved
Trial Number=3475-006, Site Number=0605, Subject ID=360483, Gender=F, Race=White, Age=22 Years, Rel Day of Study Medication Discontinuance†=71										
360483	Treatment Cycle 5	57	Hyperthyroidism	Continuing		1	N	Y	None	Not Resolved
Trial Number=3475-006, Site Number=0605, Subject ID=366008, Gender=F, Race=White, Age=74 Years, Rel Day of Study Medication Discontinuance†=100										
366008	Treatment Cycle 5	57	Hyperthyroidism	1.41 Months		1	N	Y	None	Resolved
Trial Number=3475-006, Site Number=0605, Subject ID=366351, Gender=F, Race=White, Age=46 Years, Rel Day of Study Medication Discontinuance†=										
366351	Treatment Cycle 3	29	Hyperthyroidism	4.14 Weeks		1	N	Y	None	Resolved
Trial Number=3475-006, Site Number=0605, Subject ID=367764, Gender=F, Race=White, Age=61 Years, Rel Day of Study Medication Discontinuance†=										
367764	Treatment Cycle 2	15	Hyperthyroidism	2.14 Weeks		1	N	Y	None	Resolved
Trial Number=3475-006, Site Number=0701, Subject ID=364182, Gender=M, Race=White, Age=78 Years, Rel Day of Study Medication Discontinuance†=										

C Confidential

付録 2.7.4-72 AEOSI-甲状腺機能亢進症を発現した患者の一覧

001 試験+002 試験+006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q2W										
Trial Number=3475-006, Site Number=0701, Subject ID=364182, Gender=M, Race=White, Age=78 Years, Rel Day of Study Medication Discontinuance†=										
364182	Treatment Cycle 2	15	Hyperthyroidism	4 Weeks		1	N	Y	None	Resolved
	Treatment Cycle 9	125	Hyperthyroidism	4.29 Weeks		1	N	Y	None	Resolved
	Treatment Cycle 15	209	Hyperthyroidism	Continuing		1	N	Y	None	Not Resolved
Trial Number=3475-006, Site Number=0900, Subject ID=361895, Gender=F, Race=White, Age=37 Years, Rel Day of Study Medication Discontinuance†=										
361895	Treatment Cycle 2	16	Hyperthyroidism	3.25 Months		1	N	Y	None	Resolved
Trial Number=3475-006, Site Number=0902, Subject ID=369337, Gender=M, Race=White, Age=56 Years, Rel Day of Study Medication Discontinuance†=										
369337	Treatment Cycle 3	44	Hyperthyroidism	3.43 Weeks		1	N	Y	Interrupted	Resolved
Trial Number=3475-006, Site Number=1300, Subject ID=360246, Gender=M, Race=White, Age=18 Years, Rel Day of Study Medication Discontinuance†=										
360246	Treatment Cycle 6	85	Hyperthyroidism	1.41 Months		1	N	N	None	Resolved
Trial Number=3475-006, Site Number=1600, Subject ID=361918, Gender=F, Race=White, Age=58 Years, Rel Day of Study Medication Discontinuance†=										
361918	Treatment Cycle 5	68	Hyperthyroidism	2.14 Weeks		1	N	Y	None	Resolved
Trial Number=3475-006, Site Number=1603, Subject ID=369113, Gender=M, Race=White, Age=56 Years, Rel Day of Study Medication Discontinuance†=										
369113	Treatment Cycle 8	99	Hyperthyroidism	Continuing		1	N	Y	None	Not Resolved
Trial Number=3475-006, Site Number=1708, Subject ID=363322, Gender=M, Race=White, Age=52 Years, Rel Day of Study Medication Discontinuance†=281										
363322	Treatment Cycle 3	29	Hyperthyroidism	1.38 Months		2	N	Y	None	Resolved

C Confidential

付録 2.7.4-72 AEOSI-甲状腺機能亢進症を発現した患者の一覧

001 試験+002 試験+006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q2W										
Trial Number=3475-006, Site Number=1804, Subject ID=368450, Gender=M, Race=, Age=38 Years, Rel Day of Study Medication Discontinuance†=149										
368450	Treatment Cycle 6	71	Hyperthyroidism	6.01 Months		1	N	Y	None	Resolved
Trial Number=3475-006, Site Number=1807, Subject ID=366429, Gender=M, Race=White, Age=43 Years, Rel Day of Study Medication Discontinuance†=										
366429	Treatment Cycle 8	98	Hyperthyroidism	Continuing		1	N	Y	None	Not Resolved
Trial Number=3475-006, Site Number=1819, Subject ID=365965, Gender=M, Race=White, Age=40 Years, Rel Day of Study Medication Discontinuance†=										
365965	Treatment Cycle 6	71	Hyperthyroidism	1.87 Months		1	N	Y	None	Resolved

†Relative Day of Study Medication Discontinuance is defined as the day of the last recorded dose of study medication for the subject relative to the start of study medication.

Action Taken: None = DOSE NOT CHANGED, Reduced = DOSE REDUCED, Interrupted = DRUG INTERRUPTED, Discontinued = DRUG WITHDRAWN, Increased = DOSE INCREASED, N/A = NOT APPLICABLE.

Outcome: Resolved = RECOVERED/RESOLVED, Resolving = RECOVERING/RESOLVING, Sequelae = RECOVERED/RESOLVED WITH SEQUELAE, Not resolved = NOT RECOVERED/NOT RESOLVED.

Related: Investigator-assessed relationship of the adverse event to study medication.

Grades are based on NCI CTCAE version 4.0.

(MK-3475 PN001 Database Cutoff Date: [redacted]

(MK-3475 PN002 Database Cutoff Date: 12MAY2014).

(MK-3475 PN006 Database Cutoff Date: 03SEP2014).

C Confidential

付録 2.7.4-73 AEOSI-甲状腺機能亢進症に対する副腎皮質ホルモン剤使用の一覧

001 試験+002 試験+006 試験（APaT 集団）

Subject ID	Med. Start Day	Med. Duration (Days)	Med. Name	Total Daily Dose	Frequency	Route	Prednisone Equiv.† (mg)	Adverse Event for Use	AE Start Day	AE End Day	AE Toxicity Grade
MK-3475 2 mg/kg Q3W											
Trial Number=3475-001, Site Number=0012, Subject ID=000389, Gender=F, Race=White, Age=68 Years, Rel Day of Study Medication Discontinuance‡=22											
000389	44	2	Hydrocortisone	300	Q8H	Intravenous Administration	75.00	Hyperthyroidism	40	224	2
	45	1	Hydrocortisone	200	Q6H	Intravenous Administration	50.00	Hyperthyroidism	40	224	2
	46	3	Hydrocortisone	60	TID	Oral Administration	15.00	Hyperthyroidism	40	224	2
MK-3475 10 mg/kg Q2W											
Trial Number=3475-001, Site Number=0013, Subject ID=000084, Gender=F, Race=White, Age=52 Years, Rel Day of Study Medication Discontinuance‡=43											
000084	51	8	Hydrocortisone	300	Q8H	Intravenous Drip	75.00	Hyperthyroidism	51	79	3
	59	15	Prednisone	60	BID	Oral Administration	60.00	Hyperthyroidism	51	79	3
	74	8	Prednisone	30	QD	Oral Administration	30.00	Hyperthyroidism	51	79	3
	74	8	Prednisone	20	QD	Oral Administration	20.00	Hyperthyroidism	51	79	3
	81	8	Prednisone	20	QD	Oral Administration	20.00	Hyperthyroidism	51	79	3
	81	8	Prednisone	20	QD	Oral Administration	20.00	Hyperthyroidism	51	79	3
	88	8	Prednisone	20	QD	Oral Administration	20.00	Hyperthyroidism	51	79	3
	88	8	Prednisone	10	QD	Oral Administration	10.00	Hyperthyroidism	51	79	3
	95	8	Prednisone	10	QD	Oral Administration	10.00	Hyperthyroidism	51	79	3
	95	8	Prednisone	10	QD	Oral Administration	10.00	Hyperthyroidism	51	79	3

C Confidential

付録 2.7.4-73 AEOSI-甲状腺機能亢進症に対する副腎皮質ホルモン剤使用の一覧

001 試験+002 試験+006 試験（APaT 集団）（続き）

Subject ID	Med. Start Day	Med. Duration (Days)	Med. Name	Total Daily Dose	Frequency	Route	Prednisone Equiv.† (mg)	Adverse Event for Use	AE Start Day	AE End Day	AE Toxicity Grade
	102	8	Prednisone	10	QD	Oral Administration	10.00	Hyperthyroidism	51	79	3

Med.: Medication.
Equiv.: Equivalent.
AE: Adverse Event.
†: Prednisone equivalent total daily dose.
‡Relative Day of Study Medication Discontinuance is defined as the day of the last recorded dose of study medication for the subject relative to the start of study medication.
AE start date is defined as the start day of the adverse event for the subject relative to the start of study medication.
Grades are based on NCI CTCAE version 4.0.
(MK-3475 PN001 Database Cutoff Date: [redacted].
(MK-3475 PN002 Database Cutoff Date: 12MAY2014).
(MK-3475 PN006 Database Cutoff Date: 03SEP2014).

C Confidential

付録 2.7.4-74 AEOSI-甲状腺炎を発現した患者の一覧

001 試験+002 試験+006 試験（APaT 集団）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 2 mg/kg Q3W										
Trial Number=3475-001, Site Number=0015, Subject ID=000491, Gender=M, Race=White, Age=65 Years, Rel Day of Study Medication Discontinuance†=										
000491	Treatment Cycle 2	20	Thyroiditis	1.41 Months	Mild	1		Y	N/A	Resolved
Trial Number=3475-001, Site Number=0020, Subject ID=000547, Gender=M, Race=White, Age=49 Years, Rel Day of Study Medication Discontinuance†=										
000547	Treatment Cycle 2	29	Thyroiditis	1.87 Months	Mild	1		Y		Resolved
Trial Number=3475-001, Site Number=0021, Subject ID=000483, Gender=F, Race=White, Age=52 Years, Rel Day of Study Medication Discontinuance†=85										
000483	Treatment Cycle 4	64	Thyroiditis	Continuing	Moderate	2		Y	N/A	Not Resolved
MK-3475 10 mg/kg Q3W										
Trial Number=3475-001, Site Number=0011, Subject ID=001368, Gender=F, Race=White, Age=44 Years, Rel Day of Study Medication Discontinuance†=194										
001368	Treatment Cycle 2	20	Thyroiditis	3.86 Weeks	Mild	1		Y	N/A	Resolved
	Treatment Cycle 3	46	Thyroiditis	Continuing	Moderate	2		Y		Not Resolved
Trial Number=3475-001, Site Number=0011, Subject ID=001396, Gender=F, Race=White, Age=71 Years, Rel Day of Study Medication Discontinuance†=										
001396	Treatment Cycle 4	64	Autoimmune thyroiditis	3 Weeks	Moderate	2		Y	N/A	Resolved
	Treatment Cycle 5	85	Autoimmune thyroiditis	Continuing	Mild	1		Y		Not Resolved
Trial Number=3475-001, Site Number=0016, Subject ID=001422, Gender=M, Race=White, Age=87 Years, Rel Day of Study Medication Discontinuance†=87										
001422	Treatment Cycle 4	64	Autoimmune thyroiditis	Continuing	Moderate	2		Y		Not Resolved

C Confidential

付録 2.7.4-74 AEOSI-甲状腺炎を発現した患者の一覧

001 試験+002 試験+006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W										
Trial Number=3475-001, Site Number=0021, Subject ID=001391, Gender=M, Race=White, Age=54 Years, Rel Day of Study Medication Discontinuance†=64										
001391	Treatment Cycle 2	22	Thyroiditis	Continuing	Mild	1		Y		Not Resolved
Trial Number=3475-002, Site Number=0070, Subject ID=100108, Gender=M, Race=White, Age=51 Years, Rel Day of Study Medication Discontinuance†=148										
100108	Treatment Cycle 5	106	Thyroiditis	Continuing		2	N	Y	None	Not Resolved
Trial Number=3475-002, Site Number=0080, Subject ID=100652, Gender=F, Race=White, Age=62 Years, Rel Day of Study Medication Discontinuance†=										
100652	Treatment Cycle 1	21	Autoimmune thyroiditis	3.14 Weeks		1	N	Y	None	Resolved
Trial Number=3475-002, Site Number=0142, Subject ID=100322, Gender=F, Race=White, Age=34 Years, Rel Day of Study Medication Discontinuance†=										
100322	Treatment Cycle 2	25	Autoimmune thyroiditis	3.42 Months		2	N	Y	None	Resolved
MK-3475 10 mg/kg Q2W										
Trial Number=3475-001, Site Number=0019, Subject ID=001247, Gender=M, Race=White, Age=61 Years, Rel Day of Study Medication Discontinuance†=337										
001247	Treatment Cycle 6	71	Thyroiditis	1.68 Months	Mild	1		Y	N/A	Resolved
Trial Number=3475-006, Site Number=1600, Subject ID=361918, Gender=F, Race=White, Age=58 Years, Rel Day of Study Medication Discontinuance†=										
361918	Treatment Cycle 5	68	Thyroiditis	1.48 Months		1	N	Y	None	Resolved
Trial Number=3475-006, Site Number=1700, Subject ID=365574, Gender=M, Race=White, Age=59 Years, Rel Day of Study Medication Discontinuance†=										

C Confidential

付録 2.7.4-74 AEOSI-甲状腺炎を発現した患者の一覧

001 試験+002 試験+006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q2W										
Trial Number=3475-006, Site Number=1700, Subject ID=365574, Gender=M, Race=White, Age=59 Years, Rel Day of Study Medication Discontinuance†=										
365574	Treatment Cycle 2	15	Thyroiditis	Continuing		2	Y	Y	Interrupted	Not Resolved

†Relative Day of Study Medication Discontinuance is defined as the day of the last recorded dose of study medication for the subject relative to the start of study medication.

Action Taken: None = DOSE NOT CHANGED, Reduced = DOSE REDUCED, Interrupted = DRUG INTERRUPTED, Discontinued = DRUG WITHDRAWN, Increased = DOSE INCREASED, N/A = NOT APPLICABLE.

Outcome: Resolved = RECOVERED/RESOLVED, Resolving = RECOVERING/RESOLVING, Sequelae = RECOVERED/RESOLVED WITH SEQUELAE, Not resolved = NOT RECOVERED/NOT RESOLVED.

Related: Investigator-assessed relationship of the adverse event to study medication.

Grades are based on NCI CTCAE version 4.0.

(MK-3475 PN001 Database Cutoff Date: [redacted].

(MK-3475 PN002 Database Cutoff Date: 12MAY2014).

(MK-3475 PN006 Database Cutoff Date: 03SEP2014).

C Confidential

付録 2.7.4-75 AEOSI-肝炎を発現した患者の一覧

001 試験+002 試験+006 試験（APaT 集団）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 2 mg/kg Q3W										
Trial Number=3475-001, Site Number=0015, Subject ID=000336, Gender=M, Race=White, Age=58 Years, Rel Day of Study Medication Discontinuance†=1										
000336	Safety Follow-up	22	Autoimmune hepatitis	1.08 Months	Severe	4	Y	Y	Discontinued	Resolved
Trial Number=3475-001, Site Number=0020, Subject ID=000318, Gender=F, Race=White, Age=35 Years, Rel Day of Study Medication Discontinuance†=519										
000318	Treatment Cycle 3	63	Hepatitis	1.14 Weeks	Mild	1		Y	Interrupted	Resolved
Trial Number=3475-001, Site Number=0023, Subject ID=000126, Gender=M, Race=White, Age=60 Years, Rel Day of Study Medication Discontinuance†=										
000126	Treatment Cycle 30	651	Autoimmune hepatitis	1 Weeks	Severe	3		Y	N/A	Resolved
		658	Autoimmune hepatitis	2.14 Weeks	Moderate	2		Y	Interrupted	Resolved
Trial Number=3475-002, Site Number=0001, Subject ID=100094, Gender=M, Race=White, Age=64 Years, Rel Day of Study Medication Discontinuance†=										
100094	Treatment Cycle 5	127	Autoimmune hepatitis	1.28 Months		2	N	Y	Interrupted	Resolved
Trial Number=3475-002, Site Number=0082, Subject ID=100679, Gender=F, Race=White, Age=73 Years, Rel Day of Study Medication Discontinuance†=77										
100679	Treatment Cycle 2	22	Autoimmune hepatitis	1.48 Months		3	N	Y	None	Resolved
MK-3475 10 mg/kg Q3W										
Trial Number=3475-001, Site Number=0020, Subject ID=001439, Gender=M, Race=White, Age=82 Years, Rel Day of Study Medication Discontinuance†=20										
001439	Safety Follow-up	22	Autoimmune hepatitis	2.2 Months	Moderate	2		Y	Interrupted	Resolved
Trial Number=3475-002, Site Number=0070, Subject ID=101879, Gender=M, Race=White, Age=68 Years, Rel Day of Study Medication Discontinuance†=43										

Confidential

付録 2.7.4-75 AEOSI-肝炎を発現した患者の一覧

001 試験+002 試験+006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W										
Trial Number=3475-002, Site Number=0070, Subject ID=101879, Gender=M, Race=White, Age=68 Years, Rel Day of Study Medication Discontinuance†=43										
101879	Treatment Cycle 2	21	Hepatitis	Continuing		3	N	Y	None	Not Resolved
Trial Number=3475-002, Site Number=0080, Subject ID=100913, Gender=F, Race=White, Age=53 Years, Rel Day of Study Medication Discontinuance†=1										
100913	Safety Follow-up	8	Autoimmune hepatitis	Continuing		3	Y	Y	Discontinued	Resolving
Trial Number=3475-006, Site Number=0309, Subject ID=366971, Gender=M, Race=White, Age=79 Years, Rel Day of Study Medication Discontinuance†=1										
366971	Safety Follow-up	29	Hepatitis	1.08 Months		3	Y	Y	Discontinued	Resolved
Trial Number=3475-006, Site Number=0605, Subject ID=369338, Gender=F, Race=White, Age=63 Years, Rel Day of Study Medication Discontinuance†=										
369338	Treatment Cycle 8	154	Hepatitis	1.81 Months		3	N	N	None	Resolved
Trial Number=3475-006, Site Number=0611, Subject ID=364561, Gender=M, Race=White, Age=66 Years, Rel Day of Study Medication Discontinuance†=20										
364561	Treatment Cycle 1	17	Autoimmune hepatitis	3.12 Months		3	Y	Y	Discontinued	Resolved
Trial Number=3475-006, Site Number=0611, Subject ID=365059, Gender=M, Race=White, Age=80 Years, Rel Day of Study Medication Discontinuance†=99										
365059	Treatment Cycle 2	22	Hepatitis	1.18 Months		3	Y	Y	Interrupted	Resolved
Trial Number=3475-006, Site Number=1707, Subject ID=364658, Gender=M, Race=White, Age=58 Years, Rel Day of Study Medication Discontinuance†=1										
364658	Safety Follow-up	22 22	Drug-induced liver injury Drug-induced liver injury	3.71 Weeks 4.29 Weeks		4 3	Y Y	Y Y	Discontinued Interrupted	Resolved Resolved

C Confidential

付録 2.7.4-75 AEOSI-肝炎を発現した患者の一覧

001 試験+002 試験+006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q2W										
Trial Number=3475-006, Site Number=0001, Subject ID=368185, Gender=F, Race=White, Age=42 Years, Rel Day of Study Medication Discontinuance†=279										
368185	Treatment Cycle 4	54	Autoimmune hepatitis	4.29 Weeks		3	Y	Y	Reduced	Resolved
Trial Number=3475-006, Site Number=0005, Subject ID=366940, Gender=M, Race=White, Age=65 Years, Rel Day of Study Medication Discontinuance†=										
366940	Treatment Cycle 3	40	Hepatitis	4.7 Months		3	Y	Y	Interrupted	Resolved
Trial Number=3475-006, Site Number=1824, Subject ID=360306, Gender=M, Race=White, Age=71 Years, Rel Day of Study Medication Discontinuance†=183										
360306	Safety Follow-up	191	Autoimmune hepatitis	1.77 Months		3	Y	Y	Discontinued	Resolved

†Relative Day of Study Medication Discontinuance is defined as the day of the last recorded dose of study medication for the subject relative to the start of study medication.

Action Taken: None = DOSE NOT CHANGED, Reduced = DOSE REDUCED, Interrupted = DRUG INTERRUPTED, Discontinued = DRUG WITHDRAWN, Increased = DOSE INCREASED, N/A = NOT APPLICABLE.

Outcome: Resolved = RECOVERED/RESOLVED, Resolving = RECOVERING/RESOLVING, Sequelae = RECOVERED/RESOLVED WITH SEQUELAE, Not resolved = NOT RECOVERED/NOT RESOLVED.

Related: Investigator-assessed relationship of the adverse event to study medication.

Grades are based on NCI CTCAE version 4.0.

(MK-3475 PN001 Database Cutoff Date: [redacted].

(MK-3475 PN002 Database Cutoff Date: 12MAY2014).

(MK-3475 PN006 Database Cutoff Date: 03SEP2014).

C Confidential